Cover
Cover - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Mar. 13, 2024 | Jun. 30, 2023 | |
Document Information [Line Items] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2023 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Transition Report | false | ||
Entity File Number | 001-37524 | ||
Entity Registrant Name | vTv Therapeutics Inc. | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 47-3916571 | ||
Entity Address, Address Line One | 3980 Premier Dr | ||
Entity Address, Address Line Two | Suite 310 | ||
Entity Address, City or Town | High Point | ||
Entity Address, State or Province | NC | ||
Entity Address, Postal Zip Code | 27265 | ||
City Area Code | 336 | ||
Local Phone Number | 841-0300 | ||
Title of 12(b) Security | Class A Common Stock (Par Value $0.01) | ||
Trading Symbol | VTVT | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | false | ||
Document Financial Statement Error Correction [Flag] | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 22,902,852 | ||
Documents Incorporated by Reference | Portions of the registrant’s Definitive Proxy Statement relating to its 2024 Annual Meeting of Stockholders to be filed within 120 days after December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. | ||
Entity Central Index Key | 0001641489 | ||
Document Fiscal Year Focus | 2023 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false | ||
Class A Common Stock | |||
Document Information [Line Items] | |||
Entity Common Stock, Shares Outstanding | 2,432,857 | ||
Class B Common Stock | |||
Document Information [Line Items] | |||
Entity Common Stock, Shares Outstanding | 577,349 |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2023 | |
Audit Information [Abstract] | |
Auditor Firm ID | 42 |
Auditor Name | Ernst & Young LLP |
Auditor Location | Raleigh, North Carolina |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 9,446 | $ 12,126 |
Accounts receivable, net | 102 | 173 |
Promissory note receivable | 0 | 12,243 |
Prepaid expenses and other current assets | 1,044 | 2,537 |
Current deposits | 65 | 15 |
Total current assets | 10,657 | 27,094 |
Property and equipment, net | 117 | 207 |
Operating lease right-of-use assets | 244 | 349 |
Long-term investments | 0 | 5,588 |
Total assets | 11,018 | 33,238 |
Current liabilities: | ||
Accounts payable and accrued expenses | 10,242 | 7,313 |
Current portion of operating lease liabilities | 169 | 154 |
Current portion of contract liabilities | 17 | 17 |
Current portion of notes payable | 191 | 224 |
Total current liabilities | 10,619 | 7,708 |
Contract liabilities, net of current portion | 18,669 | 18,669 |
Operating lease liabilities, net of current portion | 169 | 338 |
Warrant liability, related party | 110 | 684 |
Total liabilities | 29,567 | 27,399 |
Commitments and contingencies | ||
Redeemable noncontrolling interest | 6,131 | 16,579 |
Stockholders’ deficit: | ||
Additional paid-in capital | 256,335 | 254,757 |
Accumulated deficit | (281,042) | (265,524) |
Total stockholders’ deficit attributable to vTv Therapeutics Inc. | (24,680) | (10,740) |
Total liabilities, redeemable noncontrolling interest and stockholders’ deficit | 11,018 | 33,238 |
Class A Common Stock | ||
Stockholders’ deficit: | ||
Common stock value | 21 | 21 |
Class B Common Stock | ||
Stockholders’ deficit: | ||
Common stock value | $ 6 | $ 6 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2023 | Nov. 20, 2023 | Nov. 14, 2023 | Dec. 31, 2022 | May 04, 2021 | Dec. 31, 2020 | Jul. 29, 2015 |
Common stock par value (usd per share) | $ 0.01 | ||||||
Class A Common Stock | |||||||
Common stock par value (usd per share) | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 | 200,000,000 | 100,000,000 | 100,000,000 | ||
Common stock, shares outstanding (in shares) | 2,084,973 | ||||||
Class B Common Stock | |||||||
Common stock par value (usd per share) | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 | 100,000,000 | 100,000,000 | |||
Common stock, shares outstanding (in shares) | 577,349 | 577,349 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue | $ 0 | $ 2,018,000 | $ 4,005,000 |
Operating expenses: | |||
Research and development | 13,595,000 | 12,357,000 | 13,324,000 |
General and administrative | 11,907,000 | 12,201,000 | 12,343,000 |
Total operating expenses | 25,502,000 | 24,558,000 | 25,667,000 |
Operating loss | (25,502,000) | (22,540,000) | (21,662,000) |
Other (expense) income | (1,497,000) | (3,616,000) | 2,448,000 |
Other income – related party | 574,000 | 946,000 | 1,609,000 |
Interest income | 472,000 | 352,000 | 1,000 |
Interest expense | (13,000) | (15,000) | (12,000) |
Loss before income taxes and noncontrolling interest | (25,966,000) | (24,873,000) | (17,616,000) |
Income tax provision | 0 | 200,000 | 115,000 |
Net loss before noncontrolling interest | (25,966,000) | (25,073,000) | (17,731,000) |
Less: net loss attributable to noncontrolling interest | (5,716,000) | (5,909,000) | (4,744,000) |
Net loss attributable to vTv Therapeutics Inc. | (20,250,000) | (19,164,000) | (12,987,000) |
Net loss attributable to vTv Therapeutics Inc. common shareholders | $ (20,250,000) | $ (19,164,000) | $ (12,987,000) |
Class A Common Stock | |||
Operating expenses: | |||
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (usd per share) | $ (9.71) | $ (9.98) | $ (8.29) |
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (usd per share) | $ (9.71) | $ (9.98) | $ (8.29) |
Weighted average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) | 2,084,973 | 1,919,788 | 1,566,204 |
Weighted average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) | 2,084,973 | 1,919,788 | 1,566,204 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - USD ($) $ in Thousands | Total | Redeemable Noncontrolling Interest | Class A Common Stock | Class B Common Stock | Common Stock Class A Common Stock | Common Stock Class B Common Stock | Additional Paid-in Capital | [1] | Accumulated Deficit | |||
Beginning balance at Dec. 31, 2020 | $ 83,895 | |||||||||||
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] | ||||||||||||
Net loss | (4,744) | |||||||||||
Change in redemption value of noncontrolling interest | $ (54,189) | (54,189) | ||||||||||
Ending balance at Dec. 31, 2021 | 24,962 | |||||||||||
Beginning balance, shares (in shares) at Dec. 31, 2020 | [1] | 1,399,160 | 577,358 | |||||||||
Beginning balance at Dec. 31, 2020 | (80,102) | $ 14 | [1] | $ 6 | [1] | $ 209,914 | $ (290,036) | |||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
Net loss | (12,987) | (12,987) | ||||||||||
Share-based compensation | 2,356 | 2,356 | ||||||||||
Issuance of Class A common stock under ATM offering (in shares) | [1] | 223,221 | ||||||||||
Issuance of Class A common stock under ATM offering | 17,670 | $ 2 | [1] | 17,668 | ||||||||
Exchange of Class B Common Stock for Class A Common Stock (in shares) | [1] | 9 | (9) | |||||||||
Exercise of stock options (in shares) | [1] | 519 | ||||||||||
Exercise of stock options | 47 | 47 | ||||||||||
Issuance of Class A Common Stock under LPC agreement (in shares) | [1] | 98,543 | ||||||||||
Issuance of Class A common stock under LPC Agreement | 9,087 | $ 1 | [1] | 9,086 | ||||||||
Change in redemption value of noncontrolling interest | 54,189 | 54,189 | ||||||||||
Ending balance, shares (in shares) at Dec. 31, 2021 | [1] | 1,721,452 | 577,349 | |||||||||
Ending balance at Dec. 31, 2021 | (9,740) | $ 17 | [1] | $ 6 | [1] | 239,071 | (248,834) | |||||
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] | ||||||||||||
Change in redemption value of noncontrolling interest | (2,474) | (2,474) | ||||||||||
Ending balance at Dec. 31, 2022 | 16,579 | 16,579 | ||||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
Net loss | (19,164) | (5,909) | (19,164) | |||||||||
Share-based compensation | 1,272 | 1,272 | ||||||||||
Issuance of Class A common stock under ATM offering (in shares) | [1] | 259,657 | ||||||||||
Issuance of Class A common stock under ATM offering | 5,040 | $ 3 | [1] | 5,037 | ||||||||
Issuance of Class A Common Stock under CinRx purchase agreement, net of offering costs (in shares) | [1] | 103,864 | ||||||||||
Issuance of Class A common stock under CinRx purchase agreement, net of offering costs | 9,378 | $ 1 | [1] | 9,377 | ||||||||
Change in redemption value of noncontrolling interest | 2,474 | 2,474 | ||||||||||
Ending balance, shares (in shares) at Dec. 31, 2022 | 577,349 | 2,084,973 | [1] | 577,349 | [1] | |||||||
Ending balance at Dec. 31, 2022 | (10,740) | $ 21 | [1] | $ 6 | [1] | 254,757 | (265,524) | |||||
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] | ||||||||||||
Net loss | (5,716) | |||||||||||
Change in redemption value of noncontrolling interest | (4,732) | (4,732) | ||||||||||
Ending balance at Dec. 31, 2023 | 6,131 | $ 6,131 | ||||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
Net loss | (20,250) | (20,250) | ||||||||||
Share-based compensation | 1,578 | 1,578 | ||||||||||
Change in redemption value of noncontrolling interest | 4,732 | 4,732 | ||||||||||
Ending balance, shares (in shares) at Dec. 31, 2023 | 2,084,973 | 577,349 | 2,084,973 | [1] | 577,349 | [1] | ||||||
Ending balance at Dec. 31, 2023 | $ (24,680) | $ 21 | [1] | $ 6 | [1] | $ 256,335 | $ (281,042) | |||||
[1] (*) Adjusted retroactively for reverse stock split, see Note 1 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Cash flows from operating activities: | |||
Net loss before noncontrolling interest | $ (25,966) | $ (25,073) | $ (17,731) |
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities: | |||
Depreciation expense | 90 | 92 | 89 |
Loss from G42 Promissory Note early redemption | 313 | 0 | 0 |
Non-cash interest income | (100) | (352) | 0 |
Interest expense | 0 | 15 | 0 |
Share-based compensation expense | 1,578 | 1,272 | 2,356 |
Change in fair value of investments | 0 | 3,585 | (2,448) |
Realized gain on sale of investment in Reneo Pharmaceuticals, Inc. | (3,061) | 0 | 0 |
Impairment of investments in Anteris Bio, Inc. | 4,245 | 0 | 0 |
Change in fair value of warrants, related party | (574) | (946) | (1,609) |
Changes in assets and liabilities: | |||
Accounts receivable | 71 | (116) | 101 |
Prepaid expenses and other current assets | 1,443 | (403) | (839) |
Other assets | (105) | 0 | 0 |
Accounts payable and accrued expenses | 2,929 | (856) | 1,828 |
Contract liabilities | 0 | 6,760 | (1,005) |
Other liabilities | (154) | 0 | (50) |
Net cash used in operating activities | (19,081) | (16,022) | (19,308) |
Cash flows from investing activities: | |||
Proceed from sale of investments in Reneo Pharmaceuticals, Inc. | 4,404 | 0 | 0 |
Purchases of property and equipment | 0 | (21) | 0 |
Net cash provided by (used in) investing activities | 4,404 | (21) | 0 |
Cash flows from financing activities: | |||
Proceeds from sale of Class A common stock to collaboration partner, net of offering costs | 12,030 | 5,040 | 0 |
Proceeds from sale of Class A common stock and warrants, net of offering costs | 0 | 9,746 | 0 |
Proceeds from issuance of Class A common stock, net of offering costs | 0 | 0 | 26,757 |
Proceeds from exercise of stock options | 0 | 0 | 47 |
Proceeds from debt issuance | 566 | 776 | 887 |
Repayment of notes payable | (599) | (808) | (715) |
Net cash provided by financing activities | 11,997 | 14,754 | 26,976 |
Net (decrease) increase in cash, cash equivalents | (2,680) | (1,289) | 7,668 |
Total cash and cash equivalents, beginning of year | 12,126 | 13,415 | 5,747 |
Total cash and cash equivalents, end of year | 9,446 | 12,126 | 13,415 |
Supplemental cash flow information: | |||
Cash paid for interest | 14 | 15 | 11 |
Cash paid for income taxes | 0 | 200 | 115 |
Non-cash activities: | |||
Notes receivable recorded at fair value from collaboration partner | 0 | 11,891 | 0 |
Change in redemption value of noncontrolling interest | $ (4,732) | $ (2,474) | $ (54,189) |
Description of Business, Basis
Description of Business, Basis of Presentation and Going Concern | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Description of Business, Basis of Presentation and Going Concern | Description of Business, Basis of Presentation and Going Concern Description of Business vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Principles of Consolidation vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Consolidated Financial Statements. The assets and liabilities of vTv LLC represent substantially all of the Company's consolidated assets and liabilities with the exception of the Warrants. Various holders own non-voting interests in vTv LLC, representing a 21.7% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 78.3% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company’s Class B common stock, par value $0.01 (“Class B common stock”)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement. vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (“M&F Group”), a related party and an affiliate of MacAndrews & Forbes Incorporated (together with its affiliates “MacAndrews”) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a “Letter Agreement” and collectively, the “Letter Agreements”). vTv Therapeutics Inc. also entered into a common stock purchase agreement with G42 Investments AI Holding RSC Ltd (“G42 Investments”) (the “G42 Purchase Agreement”) and the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the “CinRx Purchase Agreement”). In addition vTv Therapeutics Inc also entered into a sales agreement with Cowen and Company, LLC (“TD Cowen”) (“TD Cowen Sales Agreement”). vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss. Reverse Stock Split On November 14, 2023, the Board of Directors of the Company approved a reverse stock split at a ratio of 1-for-40, such that every 40 shares of the Company’s Class A common stock, par value $0.01 per share (the “Class A common stock”), would be combined into one issued and outstanding share of Class A common stock, and every 40 shares of the Company’s Class B common stock, par value $0.01 per share (the “Class B common stock”), would be combined into one issued and outstanding share of Class B Common Stock (together, the “Reverse Stock Split”). On November 20, 2023, the Company filed a Certificate of Amendment to the Company’s amended and restated certificate of incorporation, as amended, with the Secretary of State of the State of Delaware, which effected a reverse stock split of our Class A common stock and Class B common stock at a ratio of 1-for-40. No fractional shares were issued in connection with the Reverse Stock Split. Any fractional shares of Class A common stock and Class B common stock to which a stockholder was entitled resulting from the Reverse Stock Split were rounded up to the nearest whole share. The Class A common stock began trading on a reverse split-adjusted basis on the Nasdaq on November 21, 2023. The Company’s Class A common stock will continue trading under the symbol “VTVT,” and the new CUSIP number for the Class A common stock following the Reverse Stock Split is 91835204. The Reverse Stock Split did not reduce the number of authorized shares of Class A and Class B common stock, which remains at 200,000,000 and 100,000,000, respectively and did not change the par value of the common stock, which remains at $0.01 per share. The Company retroactively adjusted its consolidated financial statements to reflect the Reverse Stock Split. All issued and outstanding common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise and/or vesting of all warrants to purchase shares of common stock. A proportionate adjustment was also made to the number of shares reserved for issuance pursuant to the Company’s equity incentive compensation plans to reflect the Reverse Stock Split. The common stock and additional paid-in-capital line items contained in the consolidated financial statements were adjusted to account for the Reverse Stock Split for all periods presented. The reverse stock split did not have any effect on the number of authorized shares of the Company’s preferred stock, par value of $0.01 per share, remains at 50,000,000 shares. Currently no shares of preferred stock are outstanding. Going Concern To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through December 31, 2023, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of December 31, 2023, the Company had an accumulated deficit of $281.0 million and has generated net losses in each year of its existence. As of December 31, 2023, the Company's liquidity sources included cash and cash equivalents of $9.4 million. On February 27, 2024, we entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Private Placement Investors”), pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (the “Private Placement”) (i) an aggregate of 464,377 shares (the “Private Placement Shares”) of our Class A common stock, at a purchase price of $11.81 per share, and (ii) pre-funded warrants (the “Private Placement Pre-Funded Warrants”) to purchase up to an aggregate of 3,853,997 shares of our Class A common stock (the “Private Placement Warrant Shares”) at a purchase price of $11.80 per Private Placement Pre-Funded Warrant (representing the $11.81 per Private Placement Share purchase price less the exercise price of $0.01 per Private Placement Warrant Share). We received aggregate gross proceeds from the Private Placement of approximately $51.0 million, before deducting offering expenses payable by us. The Private Placement Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire. Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements for at least the next twelve months. We plan to finance our operations into the first quarter of 2026 through the use of our cash and cash equivalents and based on current operating plans, we are evaluating several financing strategies to fund the ongoing and future clinical trials of cadisegliatin , including direct equity investments and the potential licensing and monetization of other Company programs. As of the issuance date of the Company's December 31, 2022 Form 10-K, the Company disclosed, as required under applicable accounting standards, that substantial doubt existed surrounding the Company's ability to continue as a going concern within one year of the issuance date of the December 31, 2022 consolidated financial statements. Based on the cash and cash equivalents currently available to the Company as discussed above, the Company has concluded there is no longer substantial doubt regarding the ability to continue as a going concern for at least twelve months from the issuance of the December 31, 2023 Form 10-K. On February 28, 2024, we entered into a sales agreement (the “TD Cowen Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the “TD Cowen ATM Offering”). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements See Note 20 for further details. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution. One customer represented 100% of the revenue earned during the year ended December 31, 2022, and was attributable from the satisfaction of a development milestone from the First Huadong Amendment (as defined herein). Three customers represented 100% of the revenue earned during the year ended December 31, 2021. The Company did not have any revenue during the year ended December 31, 2023. Cash and Cash Equivalents The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. Collaboration Revenue and Accounts Receivable The majority of the Company’s collaboration revenue and accounts receivable relates to its agreements to license certain of its potential drug products for development. See Note 3 for further discussion of the Company’s collaboration agreements. Accounts receivable are stated at net realizable value. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. Property and Equipment and other Long-lived Assets The Company records property and equipment at cost less accumulated depreciation. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three The estimated useful lives of property and equipment are as follows: Asset Category Useful Life (in years) Laboratory equipment 7 Computers and hardware 3-5 Furniture and office equipment 3-7 Software 3 Leasehold improvements Shorter of useful life or remaining term of lease The Company periodically assesses its property and equipment and other long-lived assets for impairment in accordance with the relevant accounting guidance. No such charges were recognized during the years ended December 31, 2023, 2022 or 2021. There were no assets held for sale at December 31, 2023 or 2022. Investments Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other (expense) income, net on the Consolidated Statements of Operations. Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment . Revenue Recognition The Company uses the revenue recognition guidance established by ASC 606, “Revenue From Contracts With Customers” (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations. The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance. The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided. Fair Value of Financial Instruments The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: • Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; • Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and • Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. Research and Development Major components of research and development costs include cash compensation to employees, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred. The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its consolidated financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study. The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Consolidated Statements of Operations as the Company receives the related goods or services. Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense. Patent Costs Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative operating expenses on the Consolidated Statements of Operations. Income Taxes From its formation on August 1, 2015, vTv Therapeutics Inc. has been subject to corporate level income taxes. Prior to July 30, 2015, the Company’s predecessor entities were taxed as partnerships and all their income and deductions flowed through and were subject to tax at the partner level. vTv Therapeutics Inc. is required to recognize deferred tax assets and liabilities for the difference between the financial reporting and tax basis of its investment in vTv LLC. The Company’s income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect management’s best assessment of estimated future taxes to be paid. The Company is subject to income taxes in both the United States and various state jurisdictions. Significant judgments and estimates are required in determining the consolidated income tax expense. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of differences between the consolidated financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period in which the enactment date occurs. The Company recognizes deferred tax assets to the extent it believes these assets are more-likely-than-not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations. The Company records uncertain tax positions on the basis of a two-step process in which (1) it determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions meeting the more-likely-than-not recognition threshold, it recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company’s Consolidated Statements of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. Noncontrolling Interest The Company records the redeemable noncontrolling interest represented by the vTv Units and the Class B common stock at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. See discussion and additional detail of the redeemable noncontrolling interest at Note 13. Segment and Geographic Information Operating segments are defined as an enterprise’s components (business activities from which it earns revenue and incurs expenses) for which discrete financial information is (1) available; and (2) is regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its President and Chief Executive Officer. The Company’s business operates in one reportable segment comprised of one operating segment. Leases The Company determines if an arrangement is a lease at inception. Balances recognized related to operating leases are included in operating lease right-of-use assets and operating lease liabilities in the Consolidated Balance Sheets. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The operating lease right-of-use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company has elected a practical expedient to not separate its lease and non-lease components and instead account for them as a single lease component. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred. Share-Based Compensation Compensation expense for share-based compensation awards issued is based on the fair value of the award at the date of grant, and compensation expense is recognized for those awards earned over the service period. The grant date fair value of stock option awards is estimated using the Black-Scholes option pricing formula. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options offering period which is derived from historical experience. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. Due to a lack of historical exercise data, the Company estimates the expected life of its outstanding stock options using the simplified method specified under Staff Accounting Bulletin Topic 14.D.2. In the event the participant’s employment by or engagement with (as a director or otherwise) the Company terminates before exercise of the options granted, the stock options granted to the participant shall immediately expire and all rights to purchase shares there under shall immediately cease and expire and be of no further force or effect, other than applicable exercise rights for vested shares that may extend past the termination date as provided for in the participant’s applicable option award agreement. The fair value of restricted stock units (“RSU”) grants is based on the market value of the Class A common stock on the date of grant. The Company also estimates the amount of share-based awards that are expected to be forfeited based on historical employee turnover rates. Comprehensive Income The Company does not have any components of other comprehensive income recorded within its Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Consolidated Financial Statements. Recently Issued Accounting Pronouncements Fair Value Measurements: In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 “ Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions ”. These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Consolidated Financial Statements. Recently Issued Accounting Pronouncements Not Yet Adopted Segment Reporting : In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): “ Improvements to Reportable Segment Disclosures ” (ASU 2023-07) . The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU on the Company's Consolidated Financial Statements and disclosures. Income Taxes : In December 2023, the FASB issued ASU 2023-09: “ Improvements to Income Tax Disclosures ” (“ASU 2023-09”). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, but we expect considerable changes to our income tax footnote. |
Collaboration Agreements
Collaboration Agreements | 12 Months Ended |
Dec. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Collaboration Agreements | Collaboration Agreements G42 Purchase Agreement and Cogna Collaborative and License Agreement The Company and G42 Investments AI Holding RSC Ltd, a private limited company (“G42 Investments”), entered into a Common Stock Purchase Agreement (the “G42 Purchase Agreement”), on May 31, 2022, pursuant to which the Company sold to G42 Investments 259,657 shares of the Company’s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the "G42 Promissory Note"). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other (expense)/income in the Company’s Consolidated Statements of Operations. G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to s pecified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and Drug Administration (“FDA”) approval in the U.S. for cadisegliatin (TTP399) , the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions. Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the “Cogna Agreement”) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (“Cogna”), which requires Cogna to work with the Company in performing clinical trials for cadisegliatin ( TP399) as well as jointly creating a global development plan to develop, market, and commercialize cadisegliatin in certain countries in the Middle East, Africa, and Central Asia (the “Partner Territory”). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercialize cadisegliatin in the Partner Territory, but will not have access to the various intellectual property (“IP”) related to the license and cadisegliatin . Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of cadisegliatin needed to conduct the trials. Under the Cogna Agreement, Cogna has the right to develop and commercialize cadisegliatin in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, cadisegliatin for commercial sale under terms to be agreed upon by the parties at a later date. Separately, the Company will conduct its clinical trials for cadisegliatin outside of the Partner Territory at its own cost. The results of each party’s clinical trials will be combined by the Company to seek FDA approval in the United States for cadisegliatin . On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC ("G42 Healthcare"), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare. The G42 Purchase Agreement also provides for, following the receipt of the cadisegliatin FDA Approval, at the option of G42 Investments, either (a) the issuance of the Company’s Class A common stock (the “Milestone Shares”) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the “Milestone Cash Payment”). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the cadisegliatin FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the cadisegliatin FDA Approval will be granted or as to the timing thereof. Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of cadisegliatin for a period of at least ten years after the first commercial sale of cadisegliatin in the Partner Territory. Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this 10-K for details of the ASU. Accordingly, the Company determined that cash consideration of $5.7 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $22.04 at the effective date. A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account. The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of cadisegliatin , and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company’s behalf to complete research and development activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (“JDC”) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance. By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall within the ASC 808 unit of account are concentrated in the clinical trials. As of December 31, 2023, the clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the year ended December 31, 2023. The Company identified certain commitments that are in the scope of ASC 606 as Cogna’s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after cadisegliatin is approved by the FDA. The Company will recognize revenue from the material right related to Cogna’s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the years ended December 31, 2023 and 2022. On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note , resulting in a loss of $0.3 million and was recognized as a component of other (expense) income in the Company’s Consolidated Statements of Operations. The G42 Promissory Note receivable was classified and accounted for under ASC 310 Receivables (“ASC 310”) and was initially measured at its fair value of $11.9 million. The Company also recorded the $18.7 million as deferred revenue in the Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the years ended December 31, 2023 and 2022 . Reneo License Agreement On December 21, 2017, the Company entered into the Reneo License Agreement, under which Reneo Pharmaceuticals, Inc. ("Reneo") obtained an exclusive, worldwide, sublicensable license to develop and commercialize the Company’s peroxisome proliferation activated receptor delta (PPAR-δ) agonist program, including the compound HPP593 , for therapeutic, prophylactic or diagnostic application in humans. Under the terms of the Reneo License Agreement, Reneo paid the Company an upfront cash payment of $3.0 million. The Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to $94.5 million. In addition, Reneo is obligated to pay the Company royalty payments at mid-single to low-double digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company has also received common stock and certain participation rights representing a minority equity interest in Reneo. Pursuant to the terms of the Reneo License Agreement, the Company is required to provide technology transfer services for a defined period after the effective date. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Reneo License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation. The Company determined that there was no discernible pattern in which the technology services would be provided during the transfer services period. As such, the Company determined that the straight-line method would be used to recognize revenue over the transfer service period. As of December 31, 2019, revenue allocated to this performance obligation was fully recognized. During the year ended December 31, 2021, $2.0 million of revenue was recognized due to the satisfaction of a development milestone under the license agreement. This amount was fully recognized as revenue during the year ended December 31, 2021, as the related performance obligation was fully satisfied. The remaining milestone payments that the Company is eligible to receive have not been included in the transaction price as of December 31, 2023, as it is not considered probable that such payments will be received. Huadong License Agreement The Company was a party to a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company’s glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the compound TTP273 , for therapeutic uses in humans or animals, in China and certain other Pacific Rim countries, including Australia and South Korea (collectively, the “Huadong License Territory”). Additionally, under the Huadong License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company’s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. Under the terms of the Huadong License Agreement, as amended, Huadong paid the Company an initial license fee of $8.0 million and is obligated to pay potential development and regulatory milestone payments totaling up to $22.0 million, with an additional potential regulatory milestone of $20.0 million if Huadong receives regulatory approval for a central nervous system indication. In addition, the Company is eligible for an additional $50.0 million in potential sales-based milestones, as well as royalty payments ranging from low-single to low-double digit rates, based on tiered sales of licensed products. On January 14, 2021, the Company entered into the first amendment to the Huadong License Agreement ("First Huadong Amendment") which eliminated the Company’s obligation to sponsor a multi-region clinical trial (the “Phase 2 MRCT”), and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $3.0 million. Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC 606 and performed a reallocation of the transaction price among the remaining performance obligations. This resulted in the recognition of approximately $1.0 million of revenue on a cumulative catch up basis during the year ended December 31, 2021. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations. The significant performance obligations under the Huadong License Agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company’s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company’s obligation to participate on the JDC, and (iv) other obligations considered to be immaterial in nature. The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service peri od. In the first quarter of 2022, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the license agreement. This amount was fully recognized as revenue during the year ended December 31, 2022 as the related performance obligation was fully satisfied. No revenue related to this combined performance obligation was recognized during the year ended December 31, 2023. A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of December 31, 2023, and revenue will be recognized using the proportional performance model over the period of the Company’s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of December 31, 2023 was immaterial. An immaterial amount of revenue for this performance obligation was recognized during the years ended December 31, 2022 and 2021. No revenue was recognized during the year ended December 31, 2023. On December 18, 2023, vTv LLC received notice from Huadong of their intent to terminate the Huadong License Agreement between vTv LLC and Huadong, dated as of December 21, 2017, as amended on January 14, 2021 (both together constituting the "Agreement"). The termination of the Agreement will not be effective until after both parties negotiate and finalize a termination agreement, to be completed at a future date. Newsoara License Agreement On May 31, 2018, the Company entered into a license agreement with Newsoara Biopharma Co., Ltd., (“Newsoara”) (the “Newsoara License Agreement”), under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company’s phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound HPP737 , in China and other Pacific Rim territories (collectively, the “Newsoara License Territory”). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company’s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory. The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the “First Newsoara Amendment”). Under the terms of the Newsoara License Agreement, Newsoara paid the Company an upfront cash payment of $2.0 million. During the year ended December 31, 2019, the Company received an additional payment of $1.0 million related to the satisfaction of a development milestone during the year. As amended, the Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to $58.5 million. In addition, Newsoara is obligated to pay the Company royalty payments at high-single to low-double digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. Pursuant to the terms of the Newsoara License Agreement, the Company is required to provide technology transfer services for a defined period after the effective date. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Newsoara License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation and the related revenue was recognized during the year ended December 31, 2018. During the year ended December 31, 2021, the transaction price for this performance obligation was increased by $1.0 million due to the satisfaction of development milestones under the license agreement. This amount was fully recognized as revenue during the year ended December 31, 2021, as the related performance obligations have been fully satisfied. The remaining milestone payments that the Company is eligible to receive have not been included in the transaction price as of December 31, 2023, as it is not considered probable that such payments will be received. Anteris License Agreement On December 11, 2020, the Company entered into a license agreement with Anteris Bio, Inc. (“Anteris”) (the “Anteris License Agreement”), under which Anteris obtained a worldwide, exclusive and sublicensable license to develop and commercialize the Company’s Nrf2 activator, HPP971 . Under the terms of the Anteris License Agreement, Anteris paid the Company an initial license fee of $2.0 million. The Company is eligible to receive additional potential development, regulatory, and sales-based milestone payments totaling up to $151.0 million. Anteris is also obligated to pay vTv royalty payments at a double-digit rate based on annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country, or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company received preferred stock representing a minority ownership interest in Anteris. Pursuant to the terms of the Anteris License Agreement, the Company was required to provide technology transfer services for a 30 day period after the effective date. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Anteris License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation and consisted of the $2.0 million initial license payment as well as the fair value of the equity interest received in Anteris of $4.2 million. The revenue related to this performance obligation was fully recognized during the year ended December 31, 2020, as the technology transfer services were considered complete as of that date. On September 25, 2023, Anteris notified the Company that it was terminating the Anteris License Agreement. Under the terms of the Anteris License Agreement, the termination would become effective ninety days following the receipt of notice, or December 24, 2023. On October 16, 2023, the Company received a Section 228(e) notice from Anteris. that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (“Plan of Dissolution”). The termination became effective on December 24, 2023, and Anteris has since liquidated its assets and ceased business. JDRF Agreement In August 2017, the Company entered into the JDRF Agreement to support the funding of the Simplici-T1 Study, an adaptive Phase 1b/2 study to explore the effects of cadisegliatin in type 1 diabetics. The Company initiated this study in the fourth quarter of 2017. The JDRF Agreement was amended in June 2021 to provide additional funding for the Company’s mechanistic study exploring the effects of cadisegliatin on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes. According to the terms of the JDRF Agreement, as amended, JDRF will provide research funding of up to $3.4 million based on the achievement of research and development milestones, with the total funding provided by JDRF not to exceed approximately one-half of the total cost of the project. Additionally, the Company has the obligation to make certain milestone payments to JDRF upon the commercialization, licensing, sale or transfer of cadisegliatin as a treatment for type 1 diabetes. Payments that the Company receives from JDRF under this agreement are recorded as restricted cash and current liabilities and recognized as an offset to research and development expense, based on the progress of the project, and only to the extent that the restricted cash is utilized to fund such development activities. As of December 31, 2023, the Company had received funding under this agreement of $3.4 million, and research and development costs were offset by $3.4 million. |
Share-Based Compensation
Share-Based Compensation | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Share-Based Compensation | Share-Based Compensation The Company has issued non-qualified stock option awards to management, other key employees, consultants, and nonemployee directors. These awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. For the years ended December 31, 2023, 2022 and 2021, the Company recognized $1.6 million, $1.3 million and $2.4 million, respectively, of compensation expense related to share-based awards. Given that the Company has established a full valuation allowance against its deferred tax assets, the Company has recognized no tax benefit related to these awards. As of December 31, 2023, the Company had total unrecognized stock-based compensation expense of approximately $1.6 million, which is expected to be recognized on a straight-line basis over a weighted average period of 2.2 years. The weighted average grant date fair value for all option grants during the years ended December 31, 2023, 2022 and 2021 was $24.78, $27.75 and $49.32 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding as well as those exercisable as of December 31, 2023, was an insignificant amount. The total fair value of stock options vested during the years ended December 31, 2023, 2022 and 2021 was $2.2 million, $1.5 million and $2.1 million, respectively. The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options granted. The fair value of stock options granted was estimated using the following assumptions during the years ended December 31, 2023, 2022 and 2021: For the Year Ended December 31, 2023 2022 2021 Expected volatility 121.01% - 126.76% 118.72% - 128.72% 118.75% - 122.17% Expected life of option, in years 5.5 - 6.1 5.2 - 6.1 5.8 - 6.0 Risk-free interest rate 3.42% - 4.61% 1.59% - 4.31% 1.00% - 1.34% Expected dividend yield 0.00% 0.00% 0.00% The following table summarizes the activity related to the stock option awards for the year ended December 31, 2023 (in thousands, except per share amounts): Number of Shares Weighted Awards outstanding at December 31, 2022 208,586 $ 87.11 Granted 43,786 29.21 Forfeited (3,125) 39.84 Awards outstanding at December 31, 2023 249,247 $ 77.53 Options exercisable at December 31, 2023 142,349 $ 112.25 Weighted average remaining contractual term 6.6 Years Options vested and expected to vest at December 31, 2023 215,205 $ 85.19 Weighted average remaining contractual term 7.3 Years Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands): 2023 2022 2021 Research and development $ 425 $ 406 $ 599 General and administrative 1,153 866 1,757 Total share-based compensation expense $ 1,578 $ 1,272 $ 2,356 |
Prepaid Expenses and Other Curr
Prepaid Expenses and Other Current Assets | 12 Months Ended |
Dec. 31, 2023 | |
Prepaid Expense and Other Assets, Current [Abstract] | |
Prepaid Expenses and Other Current Assets | Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2023 2022 Prepaid insurance $ 680 $ 755 Prepaid - other 364 1,782 Total $ 1,044 $ 2,537 |
Property and Equipment
Property and Equipment | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment | Property and Equipment Property and equipment consists of the following (in thousands): December 31, 2023 2022 Leasehold improvements $ 406 $ 406 Computers and hardware 69 69 Software 80 80 Furniture and office equipment 49 49 Total property and equipment 604 604 Less: accumulated depreciation and amortization (487) (397) Property and equipment, net $ 117 $ 207 |
Investments
Investments | 12 Months Ended |
Dec. 31, 2023 | |
Investments, Debt and Equity Securities [Abstract] | |
Investments | Investments In connection with the Reneo and Anteris License Agreements, the Company received equity ownership interests of less than 20% of the voting equity of the investees. Further, the Company does not have the ability to exercise significant influence over the investees. As of December 31, 2023 the Company has no investments classified as long-term investments in the Company’s Consolidated Balance Sheets. Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly-traded company, the Company’s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo’s initial public offering, the Company’s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of other (expense) income. The Company’s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices. On October 16, 2023, the Company received a Section 228(e) notice from Anteris that the stockholders voted in favor of the dissolution of Anteris and the adoption of the Plan of Dissolution. The Company determined the carrying value of this investment was not expected to be recoverable due to the Plan of Dissolution. As a result, the Company recorded a $4.2 million impairment charge during the year ended December 31, 2023. On October 30, 2023, the Company entered into the Repurchase Agreement with Reneo to purchase all of its common stock held by vTv LLC for total proceeds to vTv LLC of approximately $4.4 million. The Company recognized a realized gain on the sale of its investment in Reneo of $3.1 million for the year ended December 31, 2023 . The Company recognized an unrealized loss on its investment in Reneo of $3.6 million for the year ended December 31, 2022. These adjustments were recognized as a component of other (expense)/income in the Company’s Consolidated Statements of Operations. The Company’s investments consist of the following: December 31, 2023 December 31, 2022 Equity investment with readily determinable fair value: Reneo common stock $ — $ 1,343 Equity investment without readily determinable fair values assessed under the measurement alternative: Anteris preferred stock — 4,245 Total $ — $ 5,588 |
Accounts Payable and Accrued Ex
Accounts Payable and Accrued Expenses | 12 Months Ended |
Dec. 31, 2023 | |
Payables and Accruals [Abstract] | |
Accounts Payable and Accrued Expenses | Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following (in thousands): December 31, 2023 2022 Accounts payable $ 4,075 $ 2,461 Accrued development costs 4,401 3,572 Accrued compensation and related costs 1,466 788 Accrued other 300 492 Total $ 10,242 $ 7,313 |
Leases
Leases | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Leases | Leases In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election is not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. As a result of the remeasurement of the associated lease liabilities, the Company recognized additional right of use assets and corresponding lease liabilities of $0.1 million. Further, the second amendment to the lease does not include any material residual value guarantee or restrictive covenants. At December 31, 2023 and 2022, the weighted average incremental borrowing rate for operating leases held by the Company was 9.5%. At December 31, 2023 and 2022 , the weighted average remaining lease terms for the operating leases held by the Company were 1.9 years and 2.9 years, respectively. Maturities of lease liabilities for the Company’s operating leases as of December 31, 2023, were as follows (in thousands): 2024 $ 194 2025 177 2026 — 2027 — 2028 — Thereafter — Total lease payments 371 Less: imputed interest (33) Present value of lease liabilities $ 338 Operating lease cost was $0.2 million for the years ended December 31, 2023, 2022 and 2021, respectively. During the years ended December 31, 2023 and December 31, 2022, cash paid for operating leases was $0.2 million and $0.3 million, respectively. |
Notes Payable
Notes Payable | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Notes Payable | Notes Payable Notes payable consist of the following (in thousands): December 31, 2023 December 31, 2022 Short-term financing 191 224 Total notes payable 191 224 Less: Current portion (191) (224) Total notes payable, net of current portion $ — $ — |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Legal Matters From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings. Novo Nordisk In February 2007, the Company entered into an Agreement (the “Novo License Agreement”) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo Nordisk”) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as cadisegliatin . This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the Novo License Agreement, the Company has additional potential developmental and regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the year ended December 31, 2021, the Company made a payment of $2.0 million related to the satisfaction of the milestone to complete the Phase 2 trials for cadisegliatin under this agreement. No such payments were made during the years ended December 31, 2023 or 2022. |
Stockholders' Equity
Stockholders' Equity | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Stockholders' Equity | Stockholders’ Equity On July 29, 2015, the Company amended and restated its certificate of incorporation to authorize 100,000,000 shares of Class A common stock, 100,000,000 shares of Class B common stock and 50,000,000 shares of preferred stock, par value $0.01 per share. On May 4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares. On November 20, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation as amended, to effect a reverse stock split at a ratio of 1-for-40 (the "Reverse Stock Split"). Pursuant to the Reverse Stock Split, every 40 shares of the Company’s Class A common stock was combined into one issued and outstanding share of Class A Common Stock and every 40 shares of the Company’s Class B common stock was combined into one issued and outstanding share of Class B Common Stock. The Reverse Stock Split did not reduce the number of authorized shares of Class A and Class B common stock, which remained at 200,000,000 and 100,000,000 respectively and did not change the par value of the common stock, which remained at $0.01 per share. The Reverse Stock Split did not have any effect on the number of authorized shares of the Company’s preferred stock, par value of $0.01 per share, which would remain at 50,000,000 shares. Currently no shares of preferred stock are outstanding. Holders of Class A common stock and Class B common stock are entitled to one vote for each share held on all matters submitted to stockholders for their vote or approval. The holders of Class A common stock and Class B common stock will vote together as a single class on all matters submitted to stockholders for their vote or approval, except with respect to the amendment of certain provisions of the Company’s amended and restated certificate of incorporation that would alter or change the powers, preferences or special rights of the Class B common stock so as to affect them adversely, which amendments must be approved by a majority of the votes entitled to be cast by the holders of the shares affected by the amendment, voting as a separate class, or as otherwise required by applicable law. The voting power of the outstanding Class B common stock (expressed as a percentage of the total voting power of all common stock) will be equal to the percentage of vTv Units not held by the Company. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. G42 Investments Transaction On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 259,657 shares of the Company's Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the "G42 Promissory Note"). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other (expense)/income in the Company’s Consolidated Statements of Operations. CinPax and CinRx Transaction On July 22, 2022 (the “Transaction Date”), the Company entered into the CinRx Purchase Agreement with CinPax, LLC ("CinPax") and CinRx-Pharma, LLC ("CinRx"), pursuant to which the Company agreed to sell to CinPax 103,864 shares of the Company’s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022. Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to CinPax, the Company considered the closing price of the common stock on the Transaction Date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this 10-K for details of the ASU. Accordingly, the Company determined that cash consideration of $3.0 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $28.80 at the effective date. The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 30,000 shares of common stock at an initial exercise of price of approximately $28.80 per share (the “CinRx Warrants”). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 19) The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration to market and distribute the pharmaceutical product containing the Company’s proprietary candidate, cadisegliatin (the “Product”), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants. Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (“CinRx MSA”) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 14) The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par. The Company, CinPax and CinRx subsequently amended the CinRx Purchase Agreement on February 27, 2024, in connection with the Private Placement. The CinRx Purchase Agreement provides CinPax the right for two years following the Closing to designate a board observer, which has been subsequently approved by the Company’s board. Previous ATM Offering In April 2020, the Company entered into the Sales Agreement with Cantor Fitzgerald as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, shares of its Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $13.0 million by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act (the “Previous ATM Offering”). The shares were offered and sold pursuant to the Company’s shelf registration statement on Form S-3. On January 14, 2021 and June 25, 2021, the Company filed a prospectus supplement in connection with the Previous ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor Fitzgerald, as sales agent or principal, shares of the Company’s Class A common stock, by an aggregate offering price of $5.5 million and $50.0 million, respectively. The Sales Agreement with Cantor Fitzgerald was terminated on February 26, 2024. Lincoln Park Capital Transaction On November 24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement, pursuant to which the Company has the right to sell to Lincoln Park shares of the Company’s Class A common stock from time to time over the 36-month term of the LPC Purchase Agreement. The Company has issued 133,282 shares of its Class A common stock to Lincoln Park under the LPC Purchase Agreement through the date of the filing of this Annual Report on Form 10-K. The LPC Purchase Agreement expired on November 24, 2023. Letter Agreement Warrants The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, the Company has or had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews has or had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A common stock. Certain terms of each of these Letter Agreements are set forth in Note 14. The Letter Agreement Warrants were recorded as warrant liability, related party within the Company’s Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. During the years ended December 31, 2023, 2022 and 2021 the Company recognized income of $0.3 million, $0.9 million, and $1.6 million, respectively, related to the change in fair value of the Letter Agreement Warrants. These amounts were recognized as a component of other income, related party in the Consolidated Statements of Operations. Fair value of the Letter Agreement Warrants was calculated as of their issuance date using the methods described in Note 19 using the following assumptions: December 5, 2017 July 30, 2018 December 11, 2018 September 26, 2019 December 23, 2019 Expected volatility 90.00% 95.29% 104.46% 110.35% 110.41% Expected life of option, in years 7.0 7.0 7.0 7.0 7.0 Risk-free interest rate 2.80% 2.94% 2.77% 1.65% 1.84% Expected dividend yield 0.00% 0.00% 0.00% 0.00% 0.00% Loan Agreement Warrants On October 28, 2016, the Company entered into a Loan Agreement in which the Company issued to the lenders warrants to purchase a total of 3,814 shares of the Company’s Class A common stock at an exercise price of $255.60 per share which expired in October 2023. Additionally, upon funding of the second tranche on March 24, 2017, the Company issued warrants to purchase 950 shares of its Class A common stock at a per share exercise price of $236.80 per share, which aggregate exercise price represents 3.0% of the amount available under the second tranche of the Loan Agreement. The warrants will expire seven years from their date of issuance. |
Redeemable Noncontrolling Inter
Redeemable Noncontrolling Interest | 12 Months Ended |
Dec. 31, 2023 | |
Noncontrolling Interest [Abstract] | |
Redeemable Noncontrolling Interest | Redeemable Noncontrolling Interest The Company is subject to the Exchange Agreement with respect to the vTv Units representing the outstanding 21.7% noncontrolling interest in vTv LLC (see Note 1). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20 day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At December 31, 2023 and 2022, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $6.1 million and $16.6 million, respectively. Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest: December 31, 2023 2022 2021 Net loss attributable to vTv Therapeutics Inc. common shareholders $ (20,250) $ (19,164) $ (12,987) Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances — (1,061) (5,084) Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest $ (20,250) $ (20,225) $ (18,071) |
Related-Party Transactions
Related-Party Transactions | 12 Months Ended |
Dec. 31, 2023 | |
Related Party Transactions [Abstract] | |
Related-Party Transactions | Related-Party Transactions MacAndrews & Forbes Incorporated As of December 31, 2023, MacAndrews directly or indirectly controlled 577,108 shares of Class B common stock and directly or indirectly held 912,982 shares of the Company’s Class A common stock. As a result, as of December 31, 2023 MacAndrews’ holdings represented approximately 56.0% of the combined voting power of the Company’s outstanding common stock. The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below: Letter Agreements The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued the Letter Agreement Warrants to purchase additional shares of the Company’s Class A common stock. Certain terms of these Letter Agreements are set forth in the tables below: December 5, 2017 Letter Agreement July 30 11, 2018 Letter Agreement December 11, 2018 Letter Agreement March 18, 2019 Letter Agreement September 26, 2019 Letter Agreement December 23, 2019 Letter Agreement Aggregate dollar value to be sold under agreement $10.0 million $10.0 million $10.0 million $9.0 million $10.0 million $10.0 million Specified purchase price per share $ 175.20 $ 53.20 $ 73.60 $ 66.00 $ 58.40 $ 64.00 Expiration date of letter agreement December 5, 2018 July 30, 2019 December 11, 2019 March 18, 2020 September 26, 2020 December 23, 2020 Shares available to be issued under related warrants 4,956 12,966 8,513 — 10,024 9,136 Exercise price of related warrants $ 201.60 $ 61.20 $ 84.80 $ — $ 67.20 $ 73.60 Expiration date of related warrants December 5, 2024 July 30, 2025 December 11, 2025 September 26, 2026 December 23, 2026 Total shares issued as of December 31, 2023 57,077 187,969 135,869 136,363 171,232 156,250 Remaining shares to be issued as of December 31, 2023 — — — — — — Each of the December 5, 2017 and July 30, 2018 Letter Agreements resulted in a deemed capital contribution to the Company as the fair value of the financial instrument received by the Company exceeded the fair value of those financial instruments issued to MacAndrews. The December 11, 2018, March 18, 2019, September 26, 2019, and December 23, 2019 Letter Agreements resulted in a deemed distribution to MacAndrews as the fair value of the financial instruments issued to MacAndrews exceeded the fair value of the financial instrument received by the Company. Exchange Agreement Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company's Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of December 31, 2023, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement. Tax Receivable Agreement The Company and MacAndrews are party to a tax receivable agreement (the "Tax Receivable Agreement"), which provides for the payment by the Company, M&F TTP Holdings Two LLC, as successor in interest to vTv Therapeutics Holdings (“M&F”) and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability nor has it made any payments pursuant to the Tax Receivable Agreement as of December 31, 2023. Investor Rights Agreement The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf and piggyback registration rights with respect to its shares of Class A common stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. The Investor Rights Agreement was amended on February 27, 2024 to alter M&F governance rights that now entitles M&F the right to designate two members of our Board of Directors, and as part of the Private Placement, the Private Placement Investors have rights to designate three members of our Board of Directors, making it more difficult for a third party to acquire control of our Board. The agreement with the Private Placement Investors also provides that five of our directors must approve certain actions including any acquisition by a third party, which makes it more difficult for our Board of Directors to approve such a transaction. G42 Investments On May 31, 2022, the Company entered into a common stock purchase agreement with to G42 Investments pursuant to which the Company sold to G42 Investments 259,657 shares of the Company’s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid on May 31, 2023. As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company’s board of directors appointed the new director to the Company’s board on July 11, 2022. On February 28, 2023, the Company and G42 Investments entered into an amendment of the common stock purchase agreement pursuant to which G42 Investments agreed to accelerate payment of the amount due under the G42 Promissory Note. On February 28, 2023, the Company received $12.0 million from G42 Investments, which represented a 3.75% discount to the full amount due under the G42 Promissory Note, in full and final satisfaction of the promissory note, resulting in a loss of $0.3 million and was recognized as a component of other (expense)/income in the Company’s Consolidated Statements of Operations. CinRx Pharma, LLC Master Services Agreement On July 22, 2022, the Company entered into the CinRx MSA with CinRx. Under the CinRx MSA, CinRx provides the Company with consulting and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. As of October 10, 2022, the Company agreed to pay CinRx fees of up to $0.2 million per month until approximately December 2024 in respect of ongoing agreed project proposals under the CinRx MSA, plus out-of-pocket expenses incurred by CinRx on the Company’s behalf. Dr. Jonathan Isaacsohn, who was appointed as chair of the Company’s board of directors on August 9, 2022, is the President and Chief Executive Officer of CinRx. CinPax, a subsidiary of CinRx, currently holds 103,864 shares of the Company’s Class A common stock. |
Employee Benefit Plan
Employee Benefit Plan | 12 Months Ended |
Dec. 31, 2023 | |
Retirement Benefits [Abstract] | |
Employee Benefit Plan | Employee Benefit Plan The Company has a 401(k)-retirement plan in which all of its full-time employees are eligible to participate. The plan provides for the Company to make discretionary 50% matching contributions up to a maximum of 6% of employees’ eligible compensation. The Company contributed $0.1 million to the plan for each of the years ended December 31, 2023 and 2021. The Company contributed a de minimis amount to the plan for the year ended December 31, 2022. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the year ended December 31, 2023. The Company's income tax provision for the year ended December 31, 2022 and 2021 was $0.2 million and $0.1 million, respectively, representing foreign withholding taxes incurred in connection with payments received under license agreements with foreign entities. Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more likely than not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on December 31, 2023 is due to the valuation allowance against the Company’s expected net operating losses . As discussed in Note 14, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of December 31, 2023. In August 2022, the Inflation Reduction Act (“IRA”) and CHIPS and Science Act (“CHIPS Act”) were both enacted. This new legislation includes the implementation of a new corporate alternative minimum tax, an excise tax on stock buybacks, and tax incentives for energy and climate initiatives, among other provisions. The income tax provisions of the IRA or the CHIPS Act had limited applicability to the Company and did not have a material impact on the Company’s consolidated financial statements. A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows (in thousands): December 31, 2023 2022 2021 U.S. statutory tax benefit $ (5,453) $ (5,223) $ (3,699) Partnership income (federal) not subject to tax to the Company 1,200 1,241 996 Foreign withholding tax — 158 91 State taxes (net of federal benefit) (2) 28 (14) Research and development tax credit (273) (172) (173) Other (64) 40 10 Change in valuation allowance 4,592 4,128 2,904 Provision for income taxes $ — $ 200 $ 115 Effective income tax rate 0.0 % (0.8) % (0.7) % Significant components of our net deferred tax assets/(liabilities) are as follows (in thousands): December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 23,718 $ 20,314 R&D Tax Credit carryforwards 2,215 1,931 Investment in partnerships 2,726 2,202 Charitable contributions 3 3 Capital loss carryforward 380 — Total deferred tax assets 29,042 24,450 Valuation allowance (29,042) (24,450) Net deferred tax assets $ — $ — The Company assesses the available positive evidence and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of existing deferred tax assets. A significant piece of objective negative evidence evaluated was the Company’s recent operating losses. Such objective evidence limits the ability to consider other subjective evidence, such as forecasts of profitability. Based on the weight of objective evidence, including cumulative pre-tax losses in recent years, the Company concluded that its deferred tax assets were not realizable on a more-likely-than-not basis and recorded a full valuation allowance. During the year ended December 31, 2023, the Company’s valuation allowance increased by $4.6 million. The Company has federal net operating loss carryforwards of $109.5 million that will be available to offset future taxable income. Approximately, $38.8 million of these carryforwards expire in varying amounts starting in 2035 to 2037, if not utilized and are available to offset 100% of future taxable income. The remaining $70.7 million may be carried forward indefinitely but are only available to offset 80% of future taxable income. The Company has federal research and development tax credits of $2.2 million which expire in varying amounts starting in 2035 to 2043. The Company has federal capital loss carryforwards of $1.8 million which expire in 2028. The Company applies applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its consolidated financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2023, the Company had no uncertain tax positions. There are no uncertain tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve months of December 31, 2023. The Company files U.S. federal, New York, North Carolina and Virginia tax returns. The earliest open tax years that are still subject to examination by the IRS and the aforementioned state tax authorities are 2019 to 2023. |
Restructuring
Restructuring | 12 Months Ended |
Dec. 31, 2023 | |
Restructuring and Related Activities [Abstract] | |
Restructuring | Restructuring In October 2021 the Company entered into a retirement and consulting agreement with its former CEO Stephen Holcombe where he will transition to the role of Strategic Advisor to the CEO until December 31, 2022. As of December 31, 2022, the Company completed its cash payment obligations under the retirement and consulting agreement for Mr. Holcombe. The Company made cash payments under the retirement and consulting agreement of $0.6 million and $0.1 million during the year ended December 31, 2022 and 2021, respectively. In addition, the Company recorded $0.5 million and $0.2 million in severance and consulting fees respectively during the year ended December 31, 2021, on the Company’s Consolidated Statements of Operations. In December 2021, the Company announced a strategic decision to prioritize the development of its lead program cadisegliatin |
Net Loss per Share
Net Loss per Share | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
Net Loss per Share | Net Loss per Share Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts): Year Ended December 31, 2023 2022 2021 Numerator: Net loss $ (25,966) $ (25,073) $ (17,731) Less: Net loss attributable to noncontrolling interests (5,716) (5,909) (4,744) Net loss attributable to vTv Therapeutics Inc. (20,250) (19,164) (12,987) Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted $ (20,250) $ (19,164) $ (12,987) Denominator: Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted (*) 2,084,973 1,919,788 1,566,204 Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted (*) $ (9.71) $ (9.98) $ (8.29) (*) Adjusted retroactively for reverse stock split, see Note 1 Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows: Year Ended December 31, 2023 2022 2021 Class B common stock (1) (*) 577,349 577,349 577,349 Common stock options granted under the Plan (*) 249,247 208,586 176,375 Common stock warrants (*) 76,545 80,359 50,359 Total (*) 903,141 866,294 804,083 (*) Adjusted retroactively for reverse stock split, see Note 1 ________________________________________________ (1) |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature. The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments . The Company determined that the G42 Promissory Note receivable was level 2 and the fair value measurement was based on the market yield curves . The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2023, 2022 and 2021 (in thousands): Balance at December 31, 2023 Quoted Prices in Active Significant Other Observable Significant Unobservable Liabilities: Warrant liability, related party (1) $ 110 $ — $ — $ 110 Total $ 110 $ — $ — $ 110 Balance at December 31, 2022 Quoted Prices in Active Significant Other Observable Significant Unobservable Warrant liability, related party (1) $ 684 $ — $ — $ 684 Total $ 684 $ — $ — $ 684 _____________________________ (1) Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company's common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Changes in Level 3 Instruments for the years ended December 31, 2023, 2022 and 2021 Balance at January 1 Net Change in Purchases / Sales / Balance at December 31, 2023 Warrant liability, related party $ 684 $ (574) $ — $ — $ 110 Total $ 684 $ (574) $ — $ — $ 110 2022 Warrant liability, related party 1,262 (946) 368 — 684 Total $ 1,262 $ (946) $ 368 $ — $ 684 2021 Warrant liability, related party 2,871 (1,609) — — 1,262 Total $ 2,871 $ (1,609) $ — $ — $ 1,262 There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the years ended December 31, 2023, 2022 and 2021. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other (expense) income, related party in the Consolidated Statements of Operations The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility of the Company's common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants were: December 31, 2023 December 31, 2022 Range Weighted Average Range Weighted Average Expected volatility 79.96% - 89.61% 81.55% 76.94% - 85.88% 82.17% Risk-free interest rate 4.01% - 4.87% 4.15% 4.11% - 4.43% 4.19% The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of December 31, 2023, were: Expected volatility 82.1 % Expected life of options in years 3.5 Risk-free interest rate 4.0 % Expected dividend yield — % The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events Private Placement of Class A Common Shares and Pre-Funded Warrants On February 27, 2024, we entered into a securities purchase agreement with certain institutional accredited investors, pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (the “Private Placement”) (i) an aggregate of 464,377 shares of our Class A common stock, at a purchase price of $11.81 per share, and (ii) pre-funded warrants to purchase up to an aggregate of 3,853,997 shares of our Class A common stock at a purchase price of $11.80 per Private Placement Pre-Funded Warrant (representing the $11.81 per Private Placement Share purchase price less the exercise price of $0.01 per Private Placement Warrant Share). We received aggregate gross proceeds from the Private Placement of approximately $51.0 million, before deducting offering expenses payable by us. The Private Placement Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire. On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants. TD Cowen ATM |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Pay vs Performance Disclosure | |||
Net loss | $ (20,250) | $ (19,164) | $ (12,987) |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Dec. 31, 2023 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Use of Estimates | Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution. One customer represented 100% of the revenue earned during the year ended December 31, 2022, and was attributable from the satisfaction of a development milestone from the First Huadong Amendment (as defined herein). Three customers represented 100% of the revenue earned during the year ended December 31, 2021. The Company did not have any revenue during the year ended December 31, 2023. |
Cash and Cash Equivalents | Cash and Cash Equivalents |
Collaboration Revenue and Accounts Receivable | Collaboration Revenue and Accounts Receivable The majority of the Company’s collaboration revenue and accounts receivable relates to its agreements to license certain of its potential drug products for development. See Note 3 for further discussion of the Company’s collaboration agreements. Accounts receivable are stated at net realizable value. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. |
Property and Equipment and other Long-lived Assets | Property and Equipment and other Long-lived Assets The Company records property and equipment at cost less accumulated depreciation. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three The estimated useful lives of property and equipment are as follows: Asset Category Useful Life (in years) Laboratory equipment 7 Computers and hardware 3-5 Furniture and office equipment 3-7 Software 3 Leasehold improvements Shorter of useful life or remaining term of lease The Company periodically assesses its property and equipment and other long-lived assets for impairment in accordance with the relevant accounting guidance. No such charges were recognized during the years ended December 31, 2023, 2022 or 2021. There were no assets held for sale at December 31, 2023 or 2022. |
Investments | Investments Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other (expense) income, net on the Consolidated Statements of Operations. Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment |
Revenue Recognition | Revenue Recognition The Company uses the revenue recognition guidance established by ASC 606, “Revenue From Contracts With Customers” (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations. The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: • Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; • Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and • Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. |
Research and Development | Research and Development Major components of research and development costs include cash compensation to employees, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred. The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its consolidated financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study. The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Consolidated Statements of Operations as the Company receives the related goods or services. Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense. |
Patent Costs | Patent Costs Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative operating expenses on the Consolidated Statements of Operations. |
Income Taxes | Income Taxes From its formation on August 1, 2015, vTv Therapeutics Inc. has been subject to corporate level income taxes. Prior to July 30, 2015, the Company’s predecessor entities were taxed as partnerships and all their income and deductions flowed through and were subject to tax at the partner level. vTv Therapeutics Inc. is required to recognize deferred tax assets and liabilities for the difference between the financial reporting and tax basis of its investment in vTv LLC. The Company’s income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect management’s best assessment of estimated future taxes to be paid. The Company is subject to income taxes in both the United States and various state jurisdictions. Significant judgments and estimates are required in determining the consolidated income tax expense. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of differences between the consolidated financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period in which the enactment date occurs. The Company recognizes deferred tax assets to the extent it believes these assets are more-likely-than-not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations. The Company records uncertain tax positions on the basis of a two-step process in which (1) it determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions meeting the more-likely-than-not recognition threshold, it recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company’s Consolidated Statements of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. Income Taxes : In December 2023, the FASB issued ASU 2023-09: “ Improvements to Income Tax Disclosures ” (“ASU 2023-09”). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, but we expect considerable changes to our income tax footnote. |
Noncontrolling Interest | Noncontrolling Interest The Company records the redeemable noncontrolling interest represented by the vTv Units and the Class B common stock at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. See discussion and additional detail of the redeemable noncontrolling interest at Note 13. |
Segment and Geographic Information | Segment and Geographic Information Operating segments are defined as an enterprise’s components (business activities from which it earns revenue and incurs expenses) for which discrete financial information is (1) available; and (2) is regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its President and Chief Executive Officer. The Company’s business operates in one reportable segment comprised of one operating segment. |
Leases | Leases The Company determines if an arrangement is a lease at inception. Balances recognized related to operating leases are included in operating lease right-of-use assets and operating lease liabilities in the Consolidated Balance Sheets. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The operating lease right-of-use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company has elected a practical expedient to not separate its lease and non-lease components and instead account for them as a single lease component. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred. |
Share-Based Compensation | Share-Based Compensation Compensation expense for share-based compensation awards issued is based on the fair value of the award at the date of grant, and compensation expense is recognized for those awards earned over the service period. The grant date fair value of stock option awards is estimated using the Black-Scholes option pricing formula. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options offering period which is derived from historical experience. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. Due to a lack of historical exercise data, the Company estimates the expected life of its outstanding stock options using the simplified method specified under Staff Accounting Bulletin Topic 14.D.2. In the event the participant’s employment by or engagement with (as a director or otherwise) the Company terminates before exercise of the options granted, the stock options granted to the participant shall immediately expire and all rights to purchase shares there under shall immediately cease and expire and be of no further force or effect, other than applicable exercise rights for vested shares that may extend past the termination date as provided for in the participant’s applicable option award agreement. The fair value of restricted stock units (“RSU”) grants is based on the market value of the Class A common stock on the date of grant. The Company also estimates the amount of share-based awards that are expected to be forfeited based on historical employee turnover rates. |
Comprehensive Income | Comprehensive Income The Company does not have any components of other comprehensive income recorded within its Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Consolidated Financial Statements. |
Recently Issued Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted | Recently Issued Accounting Pronouncements Fair Value Measurements: In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 “ Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions ”. These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Consolidated Financial Statements. Recently Issued Accounting Pronouncements Not Yet Adopted Segment Reporting : In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): “ Improvements to Reportable Segment Disclosures ” (ASU 2023-07) . The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU on the Company's Consolidated Financial Statements and disclosures. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Summary of Estimated Useful Lives of Property and Equipment | The estimated useful lives of property and equipment are as follows: Asset Category Useful Life (in years) Laboratory equipment 7 Computers and hardware 3-5 Furniture and office equipment 3-7 Software 3 Leasehold improvements Shorter of useful life or remaining term of lease |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Assumptions Used to Estimate Fair Value of Stock Option Awards Granted | The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options granted. The fair value of stock options granted was estimated using the following assumptions during the years ended December 31, 2023, 2022 and 2021: For the Year Ended December 31, 2023 2022 2021 Expected volatility 121.01% - 126.76% 118.72% - 128.72% 118.75% - 122.17% Expected life of option, in years 5.5 - 6.1 5.2 - 6.1 5.8 - 6.0 Risk-free interest rate 3.42% - 4.61% 1.59% - 4.31% 1.00% - 1.34% Expected dividend yield 0.00% 0.00% 0.00% |
Summary of Stock Award Activity for the Period | The following table summarizes the activity related to the stock option awards for the year ended December 31, 2023 (in thousands, except per share amounts): Number of Shares Weighted Awards outstanding at December 31, 2022 208,586 $ 87.11 Granted 43,786 29.21 Forfeited (3,125) 39.84 Awards outstanding at December 31, 2023 249,247 $ 77.53 Options exercisable at December 31, 2023 142,349 $ 112.25 Weighted average remaining contractual term 6.6 Years Options vested and expected to vest at December 31, 2023 215,205 $ 85.19 Weighted average remaining contractual term 7.3 Years |
Summary of Compensation Expense Related to Grants of Stock Options | Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands): 2023 2022 2021 Research and development $ 425 $ 406 $ 599 General and administrative 1,153 866 1,757 Total share-based compensation expense $ 1,578 $ 1,272 $ 2,356 |
Prepaid Expenses and Other Cu_2
Prepaid Expenses and Other Current Assets (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Prepaid Expense and Other Assets, Current [Abstract] | |
Summary of Prepaid Expenses and Other Current Assets | Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2023 2022 Prepaid insurance $ 680 $ 755 Prepaid - other 364 1,782 Total $ 1,044 $ 2,537 |
Property and Equipment (Tables)
Property and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Summary of Property and Equipment | Property and equipment consists of the following (in thousands): December 31, 2023 2022 Leasehold improvements $ 406 $ 406 Computers and hardware 69 69 Software 80 80 Furniture and office equipment 49 49 Total property and equipment 604 604 Less: accumulated depreciation and amortization (487) (397) Property and equipment, net $ 117 $ 207 |
Investments (Tables)
Investments (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Investments, Debt and Equity Securities [Abstract] | |
Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed | The Company’s investments consist of the following: December 31, 2023 December 31, 2022 Equity investment with readily determinable fair value: Reneo common stock $ — $ 1,343 Equity investment without readily determinable fair values assessed under the measurement alternative: Anteris preferred stock — 4,245 Total $ — $ 5,588 |
Accounts Payable and Accrued _2
Accounts Payable and Accrued Expenses (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Payables and Accruals [Abstract] | |
Schedule of Accounts Payable and Accrued Liabilities | Accounts payable and accrued expenses consist of the following (in thousands): December 31, 2023 2022 Accounts payable $ 4,075 $ 2,461 Accrued development costs 4,401 3,572 Accrued compensation and related costs 1,466 788 Accrued other 300 492 Total $ 10,242 $ 7,313 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Schedule of Maturities of Lease Liabilities for Operating Leases | Maturities of lease liabilities for the Company’s operating leases as of December 31, 2023, were as follows (in thousands): 2024 $ 194 2025 177 2026 — 2027 — 2028 — Thereafter — Total lease payments 371 Less: imputed interest (33) Present value of lease liabilities $ 338 |
Notes Payable (Tables)
Notes Payable (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Notes Payable | Notes payable consist of the following (in thousands): December 31, 2023 December 31, 2022 Short-term financing 191 224 Total notes payable 191 224 Less: Current portion (191) (224) Total notes payable, net of current portion $ — $ — |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Assumptions Used to Calculate Fair Value of Warrants | Fair value of the Letter Agreement Warrants was calculated as of their issuance date using the methods described in Note 19 using the following assumptions: December 5, 2017 July 30, 2018 December 11, 2018 September 26, 2019 December 23, 2019 Expected volatility 90.00% 95.29% 104.46% 110.35% 110.41% Expected life of option, in years 7.0 7.0 7.0 7.0 7.0 Risk-free interest rate 2.80% 2.94% 2.77% 1.65% 1.84% Expected dividend yield 0.00% 0.00% 0.00% 0.00% 0.00% December 31, 2023 December 31, 2022 Range Weighted Average Range Weighted Average Expected volatility 79.96% - 89.61% 81.55% 76.94% - 85.88% 82.17% Risk-free interest rate 4.01% - 4.87% 4.15% 4.11% - 4.43% 4.19% The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of December 31, 2023, were: Expected volatility 82.1 % Expected life of options in years 3.5 Risk-free interest rate 4.0 % Expected dividend yield — % |
Redeemable Noncontrolling Int_2
Redeemable Noncontrolling Interest (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Noncontrolling Interest [Abstract] | |
Summary of Net Income Attributable to Vtv Therapeutics Inc | The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest: December 31, 2023 2022 2021 Net loss attributable to vTv Therapeutics Inc. common shareholders $ (20,250) $ (19,164) $ (12,987) Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances — (1,061) (5,084) Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest $ (20,250) $ (20,225) $ (18,071) |
Related-Party Transactions (Tab
Related-Party Transactions (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Related Party Transactions [Abstract] | |
Summary of Terms of Letter Agreements | Certain terms of these Letter Agreements are set forth in the tables below: December 5, 2017 Letter Agreement July 30 11, 2018 Letter Agreement December 11, 2018 Letter Agreement March 18, 2019 Letter Agreement September 26, 2019 Letter Agreement December 23, 2019 Letter Agreement Aggregate dollar value to be sold under agreement $10.0 million $10.0 million $10.0 million $9.0 million $10.0 million $10.0 million Specified purchase price per share $ 175.20 $ 53.20 $ 73.60 $ 66.00 $ 58.40 $ 64.00 Expiration date of letter agreement December 5, 2018 July 30, 2019 December 11, 2019 March 18, 2020 September 26, 2020 December 23, 2020 Shares available to be issued under related warrants 4,956 12,966 8,513 — 10,024 9,136 Exercise price of related warrants $ 201.60 $ 61.20 $ 84.80 $ — $ 67.20 $ 73.60 Expiration date of related warrants December 5, 2024 July 30, 2025 December 11, 2025 September 26, 2026 December 23, 2026 Total shares issued as of December 31, 2023 57,077 187,969 135,869 136,363 171,232 156,250 Remaining shares to be issued as of December 31, 2023 — — — — — — |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of Effective Income Tax Rate Reconciliation | A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows (in thousands): December 31, 2023 2022 2021 U.S. statutory tax benefit $ (5,453) $ (5,223) $ (3,699) Partnership income (federal) not subject to tax to the Company 1,200 1,241 996 Foreign withholding tax — 158 91 State taxes (net of federal benefit) (2) 28 (14) Research and development tax credit (273) (172) (173) Other (64) 40 10 Change in valuation allowance 4,592 4,128 2,904 Provision for income taxes $ — $ 200 $ 115 Effective income tax rate 0.0 % (0.8) % (0.7) % |
Schedule of Net Deferred Tax Assets/(Liabilities) | Significant components of our net deferred tax assets/(liabilities) are as follows (in thousands): December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 23,718 $ 20,314 R&D Tax Credit carryforwards 2,215 1,931 Investment in partnerships 2,726 2,202 Charitable contributions 3 3 Capital loss carryforward 380 — Total deferred tax assets 29,042 24,450 Valuation allowance (29,042) (24,450) Net deferred tax assets $ — $ — |
Net Loss per Share (Tables)
Net Loss per Share (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock | A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts): Year Ended December 31, 2023 2022 2021 Numerator: Net loss $ (25,966) $ (25,073) $ (17,731) Less: Net loss attributable to noncontrolling interests (5,716) (5,909) (4,744) Net loss attributable to vTv Therapeutics Inc. (20,250) (19,164) (12,987) Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted $ (20,250) $ (19,164) $ (12,987) Denominator: Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted (*) 2,084,973 1,919,788 1,566,204 Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted (*) $ (9.71) $ (9.98) $ (8.29) (*) Adjusted retroactively for reverse stock split, see Note 1 |
Schedule of Potentially Dilutive Securities not Included in Calculation of Dilutive Net Loss per Share | Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows: Year Ended December 31, 2023 2022 2021 Class B common stock (1) (*) 577,349 577,349 577,349 Common stock options granted under the Plan (*) 249,247 208,586 176,375 Common stock warrants (*) 76,545 80,359 50,359 Total (*) 903,141 866,294 804,083 (*) Adjusted retroactively for reverse stock split, see Note 1 ________________________________________________ (1) |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Summarizes the Conclusions Reached Regarding Fair Value Measurements | The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2023, 2022 and 2021 (in thousands): Balance at December 31, 2023 Quoted Prices in Active Significant Other Observable Significant Unobservable Liabilities: Warrant liability, related party (1) $ 110 $ — $ — $ 110 Total $ 110 $ — $ — $ 110 Balance at December 31, 2022 Quoted Prices in Active Significant Other Observable Significant Unobservable Warrant liability, related party (1) $ 684 $ — $ — $ 684 Total $ 684 $ — $ — $ 684 _____________________________ (1) Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company's common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Changes in Level 3 Instruments for the years ended December 31, 2023, 2022 and 2021 Balance at January 1 Net Change in Purchases / Sales / Balance at December 31, 2023 Warrant liability, related party $ 684 $ (574) $ — $ — $ 110 Total $ 684 $ (574) $ — $ — $ 110 2022 Warrant liability, related party 1,262 (946) 368 — 684 Total $ 1,262 $ (946) $ 368 $ — $ 684 2021 Warrant liability, related party 2,871 (1,609) — — 1,262 Total $ 2,871 $ (1,609) $ — $ — $ 1,262 |
Assumptions Used to Calculate Fair Value of Warrants | Fair value of the Letter Agreement Warrants was calculated as of their issuance date using the methods described in Note 19 using the following assumptions: December 5, 2017 July 30, 2018 December 11, 2018 September 26, 2019 December 23, 2019 Expected volatility 90.00% 95.29% 104.46% 110.35% 110.41% Expected life of option, in years 7.0 7.0 7.0 7.0 7.0 Risk-free interest rate 2.80% 2.94% 2.77% 1.65% 1.84% Expected dividend yield 0.00% 0.00% 0.00% 0.00% 0.00% December 31, 2023 December 31, 2022 Range Weighted Average Range Weighted Average Expected volatility 79.96% - 89.61% 81.55% 76.94% - 85.88% 82.17% Risk-free interest rate 4.01% - 4.87% 4.15% 4.11% - 4.43% 4.19% The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of December 31, 2023, were: Expected volatility 82.1 % Expected life of options in years 3.5 Risk-free interest rate 4.0 % Expected dividend yield — % |
Description of Business, Basi_2
Description of Business, Basis of Presentation and Going Concern - Additional Information (Detail) $ / shares in Units, $ in Thousands | 12 Months Ended | ||||||||||
Feb. 27, 2024 USD ($) $ / shares shares | Nov. 20, 2023 $ / shares shares | Nov. 14, 2023 $ / shares shares | Dec. 31, 2023 USD ($) $ / shares shares | Feb. 28, 2024 | Feb. 28, 2024 USD ($) | Feb. 28, 2024 Rate | Dec. 31, 2022 USD ($) $ / shares shares | May 04, 2021 shares | Dec. 31, 2020 shares | Jul. 29, 2015 $ / shares shares | |
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Common stock par value (usd per share) | $ 0.01 | ||||||||||
Preferred stock par value (usd per share) | $ 0.01 | $ 0.01 | |||||||||
Preferred stock, shares authorized (in shares) | shares | 50,000,000 | 50,000,000 | |||||||||
Preferred stock, shares outstanding (in shares) | shares | 0 | ||||||||||
Retained earnings (accumulated deficit) | $ | $ (281,042) | $ (265,524) | |||||||||
Cash and cash equivalents | $ | $ 9,446 | $ 12,126 | |||||||||
Subsequent Event | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Entity public float, threshold | $ | $ 75,000 | ||||||||||
Percent of public float | 33.30% | 300% | |||||||||
Subsequent Event | TD Cowen Sales Agreement | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Entity public float, threshold | $ | 75,000 | ||||||||||
Commission percent | Rate | 300% | ||||||||||
Subsequent Event | Private Placement | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Proceeds from issuance of private placement | $ | $ 51,000 | ||||||||||
Subsequent Event | Private Placement | Private Placement Pre-Funded Warrants | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Exercise price of warrants (usd per share) | $ 0.01 | ||||||||||
Class A Common Stock | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Common stock par value (usd per share) | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||
Stock split, conversion ratio | 0.025 | ||||||||||
Common stock, shares authorized (in shares) | shares | 200,000,000 | 200,000,000 | 200,000,000 | 100,000,000 | 100,000,000 | ||||||
Class A Common Stock | Subsequent Event | TD Cowen Sales Agreement | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Aggregate offering price | $ | $ 50,000 | ||||||||||
Class A Common Stock | Subsequent Event | Private Placement | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Shares sold (in shares) | shares | 464,377 | ||||||||||
Share price (usd per share) | $ 11.81 | ||||||||||
Class A Common Stock | Subsequent Event | Private Placement | Private Placement Pre-Funded Warrants | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Share price (usd per share) | $ 11.80 | ||||||||||
Warrants to purchase shares of common stock (in shares) | shares | 3,853,997 | ||||||||||
Class A Common Stock | Reverse Stock Split | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Stock split, conversion ratio | 0.025 | ||||||||||
Common stock, shares authorized (in shares) | shares | 91,835,204 | ||||||||||
Class B Common Stock | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Common stock par value (usd per share) | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||
Stock split, conversion ratio | 40 | ||||||||||
Common stock, shares authorized (in shares) | shares | 100,000,000 | 100,000,000 | 100,000,000 | 100,000,000 | |||||||
Class B Common Stock | Reverse Stock Split | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Stock split, conversion ratio | 40 | ||||||||||
vTv Therapeutics LLC | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC | 21.70% | ||||||||||
Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC | 78.30% | ||||||||||
vTv Therapeutics LLC | Class B Common Stock | |||||||||||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||||||||
Common stock par value (usd per share) | $ 0.01 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Additional Information (Detail) | 12 Months Ended | ||
Dec. 31, 2023 USD ($) Segment | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Summary Of Significant Accounting Policies [Line Items] | |||
Revenue | $ 0 | $ 2,018,000 | $ 4,005,000 |
Asset impairment charges | 0 | 0 | $ 0 |
Assets held for sale | 0 | $ 0 | |
Significant interest or penalties incurred related to income taxes | $ 0 | ||
Number of reportable segment | Segment | 1 | ||
Number of operating segments | Segment | 1 | ||
Minimum | |||
Summary Of Significant Accounting Policies [Line Items] | |||
Property and equipment, estimated useful lives | 3 years | ||
Maximum | |||
Summary Of Significant Accounting Policies [Line Items] | |||
Property and equipment, estimated useful lives | 10 years | ||
Revenue | Customer | One Customer | |||
Summary Of Significant Accounting Policies [Line Items] | |||
Concentration risk percentage | 100% | ||
Revenue | Customer | Three Customers | |||
Summary Of Significant Accounting Policies [Line Items] | |||
Concentration risk percentage | 100% |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Detail) | Dec. 31, 2023 |
Minimum | |
Summary Of Significant Accounting Policies [Line Items] | |
Property and equipment, estimated useful lives | 3 years |
Maximum | |
Summary Of Significant Accounting Policies [Line Items] | |
Property and equipment, estimated useful lives | 10 years |
Laboratory equipment | |
Summary Of Significant Accounting Policies [Line Items] | |
Property and equipment, estimated useful lives | 7 years |
Computers and hardware | Minimum | |
Summary Of Significant Accounting Policies [Line Items] | |
Property and equipment, estimated useful lives | 3 years |
Computers and hardware | Maximum | |
Summary Of Significant Accounting Policies [Line Items] | |
Property and equipment, estimated useful lives | 5 years |
Furniture and office equipment | Minimum | |
Summary Of Significant Accounting Policies [Line Items] | |
Property and equipment, estimated useful lives | 3 years |
Furniture and office equipment | Maximum | |
Summary Of Significant Accounting Policies [Line Items] | |
Property and equipment, estimated useful lives | 7 years |
Software | |
Summary Of Significant Accounting Policies [Line Items] | |
Property and equipment, estimated useful lives | 3 years |
Leasehold improvements | |
Summary Of Significant Accounting Policies [Line Items] | |
Property and equipment, estimated useful lives | Useful Life, Lease Term [Member] |
Collaboration Agreements - Addi
Collaboration Agreements - Additional Information (Detail) - USD ($) | 1 Months Ended | 12 Months Ended | ||||||||||
Feb. 28, 2023 | May 31, 2022 | Dec. 11, 2020 | Dec. 21, 2017 | May 31, 2018 | Aug. 31, 2017 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2019 | Sep. 25, 2023 | Jan. 14, 2021 | |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
Proceeds from collection of notes receivable | $ 12,000,000 | |||||||||||
Revenue | $ 0 | $ 2,018,000 | $ 4,005,000 | |||||||||
Discount rate | 3.75% | |||||||||||
Gain (loss) on extinguishment of debt | (313,000) | 0 | 0 | |||||||||
Contract liabilities, net of current portion | 18,669,000 | 18,669,000 | ||||||||||
License agreement termination, period | 90 days | |||||||||||
Research and development | 13,595,000 | 12,357,000 | 13,324,000 | |||||||||
G42 Investments | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
Shares sold (in shares) | 259,657 | |||||||||||
Share price (usd per share) | $ 96.40 | |||||||||||
Sale of Stock, consideration received on transaction, gross | $ 25,000,000 | |||||||||||
Aggregate gross purchase price | 12,500,000 | |||||||||||
Accounts and financing receivable, after allowance for credit loss | 12,500,000 | |||||||||||
Proceeds from collection of notes receivable | $ 12,000,000 | |||||||||||
Discount rate | 3.75% | |||||||||||
Gain (loss) on extinguishment of debt | $ (300,000) | |||||||||||
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
Sale of Stock, consideration received on transaction, gross | 25,000,000 | |||||||||||
Accounts and financing receivable, after allowance for credit loss | 12,500,000 | |||||||||||
Revenue | 0 | |||||||||||
Gain (loss) on extinguishment of debt | $ (300,000) | |||||||||||
Contingent consideration transferred, aggregate share value | 30,000,000 | |||||||||||
Contingent consideration transferred, cash | 30,000,000 | |||||||||||
Contract liabilities, net of current portion | 18,700,000 | 18,700,000 | ||||||||||
Note receivable, discount paid | 600,000 | |||||||||||
Revenue from collaborative arrangement | 0 | |||||||||||
Receivables, fair value disclosure | 11,900,000 | |||||||||||
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments | Class A Common Stock | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
Common stock outstanding | $ 5,700,000 | |||||||||||
Share price (usd per share) | $ 22.04 | |||||||||||
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | Cogna | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
Collaborative arrangement, royalties receivable, period | 10 years | |||||||||||
Collaborative Arrangements | Reneo | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
License fee received | $ 3,000,000 | |||||||||||
Collaboration revenue recognized | 2,000,000 | |||||||||||
Collaborative Arrangements | Reneo | Maximum | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
Potential development and regulatory milestone payments | 94,500,000 | |||||||||||
Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
License fee received | 8,000,000 | |||||||||||
Potential regulatory milestone payments based on regulatory approval | 20,000,000 | |||||||||||
Potential sales-based milestones based on tiered sales of licensed products | 50,000,000 | |||||||||||
Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
Potential development and regulatory milestone payments | $ 3,000,000 | |||||||||||
Maximum contribution amount to clinical trial | $ 3,000,000 | |||||||||||
Unrecognized amount of transaction price allocated to performance obligation | 1,000,000 | |||||||||||
Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT | License and Technology Transfer Services of Chemistry and Manufacturing Know-How | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
Adjustments to transaction price for performance obligations | 0 | $ 2,000,000 | ||||||||||
Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Maximum | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
Potential development and regulatory milestone payments | $ 22,000,000 | |||||||||||
Collaborative Arrangements | Newsoara Biopharma Co., Ltd. | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
License fee received | $ 2,000,000 | |||||||||||
Collaboration revenue recognized | $ 1,000,000 | |||||||||||
Potential development and regulatory milestone payments | $ 58,500,000 | |||||||||||
Collaborative Arrangements | Newsoara Biopharma Co., Ltd. | License And Technology Transfer Services | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
Revenue recognized from change in estimated transaction prices | 1,000,000 | |||||||||||
Collaborative Arrangements | Anteris Bio, Inc. | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
License fee received | $ 2,000,000 | |||||||||||
Potential development and regulatory milestone payments | $ 151,000,000 | |||||||||||
Collaborative Arrangements | Anteris Bio, Inc. | License and Technology Transfer Services of Chemistry and Manufacturing Know-How | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
License fee received | 2,000,000 | |||||||||||
Equity interest received | $ 4,200,000 | |||||||||||
Collaborative Arrangements | JDRF | ||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||
Maximum research funding receivable achievement based on research and development milestones | $ 3,400,000 | |||||||||||
Maximum funding percentage of research and development milestones | 50% | |||||||||||
Funding received | 3,400,000 | |||||||||||
Research and development | $ 3,400,000 |
Share-Based Compensation - Addi
Share-Based Compensation - Additional Information (Detail) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Non-qualified stock option awards vesting period | 3 years | 3 years | 3 years |
Non-qualified stock option awards expiration term | 10 years | 10 years | 10 years |
Compensation expense related to share-based awards | $ 1,578,000 | $ 1,272,000 | $ 2,356,000 |
Tax benefit related to stock option awards | 0 | 0 | |
Stock options vested, fair value | 2,200,000 | $ 1,500,000 | $ 2,100,000 |
Employee Stock Option | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Unrecognized compensation cost related to non-vested share-based compensation arrangements | $ 1,600,000 | ||
Weighted average period to recognize unrecognized share-based compensation cost | 2 years 2 months 12 days | ||
Weighted average grant date fair value of options granted (usd per share) | $ 24.78 | $ 27.75 | $ 49.32 |
Share-Based Compensation - Assu
Share-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Option Awards Granted (Detail) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Schedule of Share Based Compensation Valuation Assumptions [Line Items] | |||
Expected volatility, minimum | 121.01% | 118.72% | 118.75% |
Expected volatility, maximum | 126.76% | 128.72% | 122.17% |
Risk-free interest rate, minimum | 3.42% | 1.59% | 1% |
Risk-free interest rate, maximum | 4.61% | 4.31% | 1.34% |
Expected dividend yield | 0% | 0% | 0% |
Minimum | |||
Schedule of Share Based Compensation Valuation Assumptions [Line Items] | |||
Expected life of option, in years | 5 years 6 months | 5 years 2 months 12 days | 5 years 9 months 18 days |
Maximum | |||
Schedule of Share Based Compensation Valuation Assumptions [Line Items] | |||
Expected life of option, in years | 6 years 1 month 6 days | 6 years 1 month 6 days | 6 years |
Share-Based Compensation - Summ
Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail) | 12 Months Ended |
Dec. 31, 2023 $ / shares shares | |
Number of Shares | |
Award outstanding, beginning balance (in shares) | shares | 208,586 |
Granted (in shares) | shares | 43,786 |
Forfeited (in shares) | shares | (3,125) |
Award outstanding, ending balance (in shares) | shares | 249,247 |
Options exercisable (in shares) | shares | 142,349 |
Weighted average remaining contractual term | 6 years 7 months 6 days |
Options vested and expected to vest (in shares) | shares | 215,205 |
Weighted average remaining contractual term | 7 years 3 months 18 days |
Weighted Average Exercise Price | |
Awards outstanding, beginning balance (usd per share) | $ / shares | $ 87.11 |
Granted (usd per share) | $ / shares | 29.21 |
Forfeited (usd per share) | $ / shares | 39.84 |
Awards outstanding, ending balance (usd per share) | $ / shares | 77.53 |
Options exercisable (usd per share) | $ / shares | 112.25 |
Options vested and expected to vest (usd per share) | $ / shares | $ 85.19 |
Share-Based Compensation - Su_2
Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | |||
Total share-based compensation expense | $ 1,578 | $ 1,272 | $ 2,356 |
Research and development | |||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | |||
Total share-based compensation expense | 425 | 406 | 599 |
General and administrative | |||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | |||
Total share-based compensation expense | $ 1,153 | $ 866 | $ 1,757 |
Prepaid Expenses and Other Cu_3
Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Prepaid Expense and Other Assets, Current [Abstract] | ||
Prepaid insurance | $ 680 | $ 755 |
Prepaid - other | 364 | 1,782 |
Total | $ 1,044 | $ 2,537 |
Property and Equipment - Summar
Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Property Plant And Equipment [Line Items] | ||
Total property and equipment | $ 604 | $ 604 |
Less: accumulated depreciation and amortization | (487) | (397) |
Property and equipment, net | 117 | 207 |
Leasehold improvements | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 406 | 406 |
Computers and hardware | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 69 | 69 |
Software | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 80 | 80 |
Furniture and office equipment | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | $ 49 | $ 49 |
Property and Equipment - Additi
Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |||
Depreciation expense | $ 90 | $ 92 | $ 89 |
Investments - Additional Inform
Investments - Additional Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | |||
Oct. 30, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Equity Securities With Readily Determinable Fair Value [Line Items] | ||||
Impairment charges | $ 4,200 | |||
Unrealized gain (loss) on investment | 0 | $ (3,585) | $ 2,448 | |
Reneo | ||||
Equity Securities With Readily Determinable Fair Value [Line Items] | ||||
Stock repurchased during period | $ 4,400 | |||
Unrealized gain (loss) on investment | $ 3,100 | $ (3,600) | ||
Maximum | ||||
Equity Securities With Readily Determinable Fair Value [Line Items] | ||||
Equity method investments, ownership percentage | 20% |
Investments - Schedule of Equit
Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Investments, Debt and Equity Securities [Abstract] | ||
Equity investment with readily determinable fair value: | $ 0 | $ 1,343 |
Equity investment without readily determinable fair values assessed under the measurement alternative: | 0 | 4,245 |
Long-term investments | $ 0 | $ 5,588 |
Accounts Payable and Accrued _3
Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Payables and Accruals [Abstract] | ||
Accounts payable | $ 4,075 | $ 2,461 |
Accrued development costs | 4,401 | 3,572 |
Accrued compensation and related costs | 1,466 | 788 |
Accrued other | 300 | 492 |
Total | $ 10,242 | $ 7,313 |
Leases - Additional Information
Leases - Additional Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Nov. 30, 2022 | |
Leases [Abstract] | ||||
Renewal term | 5 years | |||
Termination period | 3 years | |||
Operating lease right-of-use assets | $ 244 | $ 349 | $ 100 | |
Present value of lease liabilities | $ 338 | $ 100 | ||
Weighted average incremental borrowing rate | 9.50% | 9.50% | ||
Remaining operating lease term | 1 year 10 months 24 days | 2 years 10 months 24 days | ||
Operating lease cost | $ 200 | $ 200 | $ 200 | |
Cash paid for operating lease | $ 200 | $ 300 |
Leases - Schedule of Maturities
Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Nov. 30, 2022 |
Leases [Abstract] | ||
2024 | $ 194 | |
2025 | 177 | |
2026 | 0 | |
2027 | 0 | |
2028 | 0 | |
Thereafter | 0 | |
Total lease payments | 371 | |
Less: imputed interest | (33) | |
Present value of lease liabilities | $ 338 | $ 100 |
Notes Payable - Schedule of Not
Notes Payable - Schedule of Notes Payable (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Debt Disclosure [Abstract] | ||
Short-term financing | $ 191 | $ 224 |
Total notes payable | 191 | 224 |
Less: Current portion | (191) | (224) |
Total notes payable, net of current portion | $ 0 | $ 0 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) - Novo License Agreement - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Feb. 28, 2007 |
Developmental And Regulatory Milestone Payment | Maximum | Other Indication | ||||
Commitments And Contingencies [Line Items] | ||||
Potential milestone payment | $ 115,000,000 | |||
Developmental And Regulatory Milestone Payment | Maximum | Type 1 Diabetes | ||||
Commitments And Contingencies [Line Items] | ||||
Potential milestone payment | 9,000,000 | |||
Developmental And Regulatory Milestone Payment | Maximum | Type 2 Diabetes | ||||
Commitments And Contingencies [Line Items] | ||||
Potential milestone payment | 50,500,000 | |||
Sales-based Milestones Payment | ||||
Commitments And Contingencies [Line Items] | ||||
Potential milestone payment | $ 75,000,000 | |||
Satisfaction of Milestone Payment | ||||
Commitments And Contingencies [Line Items] | ||||
Potential milestone payment | $ 0 | $ 0 | $ 2,000,000 |
Stockholders' Equity - Addition
Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands | 12 Months Ended | |||||||||||||||||
Nov. 20, 2023 $ / shares shares | Feb. 28, 2023 USD ($) | Jul. 22, 2022 USD ($) $ / shares shares | May 31, 2022 USD ($) $ / shares shares | May 04, 2021 shares | Dec. 08, 2020 shares | Apr. 30, 2020 USD ($) $ / shares | Mar. 24, 2017 $ / shares shares | Oct. 28, 2016 $ / shares shares | Dec. 31, 2023 USD ($) Vote exercisable $ / shares shares | Dec. 31, 2022 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) shares | Feb. 27, 2024 | Nov. 14, 2023 $ / shares | Jun. 25, 2021 USD ($) | Jan. 14, 2021 USD ($) | Dec. 31, 2020 shares | Jul. 29, 2015 $ / shares shares | |
Class Of Stock [Line Items] | ||||||||||||||||||
Preferred stock, shares authorized (in shares) | shares | 50,000,000 | 50,000,000 | ||||||||||||||||
Common stock par value (usd per share) | $ / shares | $ 0.01 | |||||||||||||||||
Preferred stock par value (usd per share) | $ / shares | $ 0.01 | $ 0.01 | ||||||||||||||||
Preferred stock, shares outstanding (in shares) | shares | 0 | |||||||||||||||||
Capital stock, shares authorized (in shares) | shares | 350,000,000 | 250,000,000 | ||||||||||||||||
Proceeds from collection of notes receivable | $ 12,000 | |||||||||||||||||
Discount rate | 3.75% | |||||||||||||||||
Gain (loss) on extinguishment of debt | $ (313) | $ 0 | $ 0 | |||||||||||||||
letter agreement, maximum exercisable times | exercisable | 3 | |||||||||||||||||
Change in fair value of consideration warrants expense | $ 300 | $ 900 | $ 1,600 | |||||||||||||||
CinRx Investment | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Shares sold (in shares) | shares | 103,864 | |||||||||||||||||
Share price (usd per share) | $ / shares | $ 96.40 | |||||||||||||||||
Sale of Stock, consideration received on transaction, gross | $ 10,000 | |||||||||||||||||
Aggregate gross purchase price | 6,000 | |||||||||||||||||
Accounts and financing receivable, after allowance for credit loss | $ 4,000 | |||||||||||||||||
Expected life of options in years | 5 years | |||||||||||||||||
CinRx Investment | Subsequent Event | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Right of purchase of common stock from issuance of private placement, wait period | 2 years | |||||||||||||||||
G42 Investments | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Shares sold (in shares) | shares | 259,657 | |||||||||||||||||
Share price (usd per share) | $ / shares | $ 96.40 | |||||||||||||||||
Sale of Stock, consideration received on transaction, gross | $ 25,000 | |||||||||||||||||
Aggregate gross purchase price | 12,500 | |||||||||||||||||
Accounts and financing receivable, after allowance for credit loss | $ 12,500 | |||||||||||||||||
Sale of stock, consideration, receivable, term | 1 year | |||||||||||||||||
Proceeds from collection of notes receivable | $ 12,000 | |||||||||||||||||
Discount rate | 3.75% | |||||||||||||||||
Gain (loss) on extinguishment of debt | $ (300) | |||||||||||||||||
Loan and Security Agreement | Horizon Technology Finance Corporation and Silicon Valley Bank | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Warrants expiration period | 7 years | |||||||||||||||||
Loan and Security Agreement | Horizon Technology Finance Corporation and Silicon Valley Bank | Tranche One | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Warrants to purchase shares of common stock (in shares) | shares | 3,814 | |||||||||||||||||
Exercise price of warrants (usd per share) | $ / shares | $ 255.60 | |||||||||||||||||
Loan and Security Agreement | Horizon Technology Finance Corporation and Silicon Valley Bank | Tranche Two | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Warrants to purchase shares of common stock (in shares) | shares | 950 | |||||||||||||||||
Exercise price of warrants (usd per share) | $ / shares | $ 236.80 | |||||||||||||||||
Warrant shares percentage issued of loan amount | 3% | |||||||||||||||||
LPC Purchase Agreement | Related Party | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Agreement term | 36 months | |||||||||||||||||
Class A Common Stock | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Common stock, shares authorized (in shares) | shares | 200,000,000 | 200,000,000 | 200,000,000 | 100,000,000 | 100,000,000 | |||||||||||||
Common stock par value (usd per share) | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||
Increase in shares authorized (in shares) | shares | 100,000,000 | |||||||||||||||||
Stock split, conversion ratio | 0.025 | |||||||||||||||||
Common stock, vote per share | Vote | 1 | |||||||||||||||||
Class A Common Stock | CinRx Investment | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Share price (usd per share) | $ / shares | $ 28.80 | |||||||||||||||||
Aggregate gross purchase price | $ 3,000 | |||||||||||||||||
Class A Common Stock | Cantor Fitzgerald | ATM Offering | Related Party | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Common stock par value (usd per share) | $ / shares | $ 0.01 | |||||||||||||||||
Aggregate offering price | $ 50,000 | $ 5,500 | ||||||||||||||||
Class A Common Stock | Cantor Fitzgerald | ATM Offering | Maximum | Related Party | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Aggregate offering price | $ 13,000 | |||||||||||||||||
Class A Common Stock | LPC Purchase Agreement | Related Party | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Shares registered under the LPC agreement (in shares) | shares | 133,282 | |||||||||||||||||
Class B Common Stock | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Common stock, shares authorized (in shares) | shares | 100,000,000 | 100,000,000 | 100,000,000 | 100,000,000 | ||||||||||||||
Common stock par value (usd per share) | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||
Stock split, conversion ratio | 40 | |||||||||||||||||
Common stock, vote per share | Vote | 1 | |||||||||||||||||
Common Stock | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Common stock, shares authorized (in shares) | shares | 300,000,000 | 200,000,000 | ||||||||||||||||
Common Stock | CinRx Investment | ||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||
Warrants to purchase shares of common stock (in shares) | shares | 30,000 | |||||||||||||||||
Exercise price of warrants (usd per share) | $ / shares | $ 28.80 | |||||||||||||||||
Warrants and rights outstanding | $ 400 |
Stockholders' Equity - Assumpti
Stockholders' Equity - Assumptions Used to Calculate Fair Value of Warrants (Detail) - Letter Agreement Warrants | Dec. 23, 2019 yr | Sep. 26, 2019 yr | Dec. 11, 2018 yr | Jul. 30, 2018 yr | Dec. 05, 2017 yr |
Expected volatility | |||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | |||||
Measurement input | 110.41 | 110.35 | 104.46 | 95.29 | 90 |
Expected life of option, in years | |||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | |||||
Measurement input | 7 | 7 | 7 | 7 | 7 |
Risk-free interest rate | |||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | |||||
Measurement input | 1.84 | 1.65 | 2.77 | 2.94 | 2.80 |
Expected dividend yield | |||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | |||||
Measurement input | 0 | 0 | 0 | 0 | 0 |
Redeemable Noncontrolling Int_3
Redeemable Noncontrolling Interest - Additional Information (Detail) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Noncontrolling Interest [Line Items] | ||
Redemption amount of noncontrolling interest | $ 6.1 | $ 16.6 |
Class A Common Stock | ||
Noncontrolling Interest [Line Items] | ||
Number of days used to determine exchange value based on weighted average price of Class A common stock | 20 days | |
Class A Common Stock | Exchange of Redeemable Non controlling Interest To Class A Common Stock | ||
Noncontrolling Interest [Line Items] | ||
Stock conversion ratio | 1 | |
vTv Therapeutics LLC | ||
Noncontrolling Interest [Line Items] | ||
Noncontrolling interest ownership percentage | 21.70% |
Redeemable Noncontrolling Int_4
Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Noncontrolling Interest [Abstract] | |||
Net loss attributable to vTv Therapeutics Inc. common shareholders | $ (20,250) | $ (19,164) | $ (12,987) |
Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances | 0 | (1,061) | (5,084) |
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest | $ (20,250) | $ (20,225) | $ (18,071) |
Related-Party Transactions - Ad
Related-Party Transactions - Additional Information (Detail) $ / shares in Units, $ in Thousands | 12 Months Ended | |||||
Feb. 28, 2023 USD ($) | May 31, 2022 USD ($) $ / shares shares | Dec. 31, 2023 USD ($) shares | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Oct. 10, 2022 USD ($) | |
Related Party Transaction [Line Items] | ||||||
Proceeds from collection of notes receivable | $ 12,000 | |||||
Discount rate | 3.75% | |||||
Gain (loss) on extinguishment of debt | $ (313) | $ 0 | $ 0 | |||
Class A Common Stock | CinRx Pharma, LLC | ||||||
Related Party Transaction [Line Items] | ||||||
Shares held by related party (in shares) | shares | 103,864 | |||||
Class A Common Stock | Exchange of Redeemable Non controlling Interest To Class A Common Stock | ||||||
Related Party Transaction [Line Items] | ||||||
Stock conversion ratio | 1 | |||||
Related Party | MacAndrews & Forbes Incorporated | ||||||
Related Party Transaction [Line Items] | ||||||
Ownership percentage of majority owner | 56% | |||||
Amount of cash savings percentage | 85% | |||||
Related Party | G42 Investments | ||||||
Related Party Transaction [Line Items] | ||||||
Sale of Stock, consideration received on transaction, gross | $ 25,000 | |||||
Aggregate gross purchase price | 12,500 | |||||
Accounts and financing receivable, after allowance for credit loss | $ 12,500 | |||||
Proceeds from collection of notes receivable | $ 12,000 | |||||
Discount rate | 3.75% | |||||
Related Party | Master Service Agreement | ||||||
Related Party Transaction [Line Items] | ||||||
Due to related parties, monthly amount | $ 200 | |||||
Related Party | G42 Investments | ||||||
Related Party Transaction [Line Items] | ||||||
Gain (loss) on extinguishment of debt | $ (300) | |||||
Related Party | Class B Common Stock | MacAndrews & Forbes Incorporated | ||||||
Related Party Transaction [Line Items] | ||||||
Shares held by related party (in shares) | shares | 577,108 | |||||
Related Party | Class A Common Stock | MacAndrews & Forbes Incorporated | ||||||
Related Party Transaction [Line Items] | ||||||
Shares held by related party (in shares) | shares | 912,982 | |||||
Related Party | Class A Common Stock | G42 Investments | ||||||
Related Party Transaction [Line Items] | ||||||
Shares sold (in shares) | shares | 259,657 | |||||
Share price (usd per share) | $ / shares | $ 96.40 | |||||
Related Party | Class A Common Stock | Letter Agreements With MacAndrews | ||||||
Related Party Transaction [Line Items] | ||||||
Letter agreement time period | 1 year | |||||
Related Party | Class A Common Stock | Exchange of Redeemable Non controlling Interest To Class A Common Stock | MacAndrews & Forbes Incorporated | ||||||
Related Party Transaction [Line Items] | ||||||
Stock conversion ratio | 1 |
Related-Party Transactions - Su
Related-Party Transactions - Summary of Terms of Letter Agreements (Detail) - MacAndrews & Forbes Incorporated - Class A Common Stock - USD ($) $ / shares in Units, $ in Millions | Dec. 23, 2019 | Sep. 26, 2019 | Mar. 18, 2019 | Dec. 11, 2018 | Jul. 30, 2018 | Dec. 05, 2017 |
2017 Letter Agreement | ||||||
Class Of Warrant Or Right [Line Items] | ||||||
Aggregate dollar value to be sold under agreement | $ 10 | |||||
Specified purchase price per share (usd per share) | $ 175.20 | |||||
Shares available to be issued under related warrants (in shares) | 4,956 | |||||
Exercise price of related warrants (usd per share) | $ 201.60 | |||||
Total shares issued as of December 31, 2023 (in shares) | 57,077 | |||||
2018 Letter Agreement | ||||||
Class Of Warrant Or Right [Line Items] | ||||||
Aggregate dollar value to be sold under agreement | $ 10 | $ 10 | ||||
Specified purchase price per share (usd per share) | $ 73.60 | $ 53.20 | ||||
Shares available to be issued under related warrants (in shares) | 8,513 | 12,966 | ||||
Exercise price of related warrants (usd per share) | $ 84.80 | $ 61.20 | ||||
Total shares issued as of December 31, 2023 (in shares) | 135,869 | 187,969 | ||||
2019 Letter Agreement | ||||||
Class Of Warrant Or Right [Line Items] | ||||||
Aggregate dollar value to be sold under agreement | $ 10 | $ 10 | $ 9 | |||
Specified purchase price per share (usd per share) | $ 64 | $ 58.40 | $ 66 | |||
Shares available to be issued under related warrants (in shares) | 9,136 | 10,024 | ||||
Exercise price of related warrants (usd per share) | $ 73.60 | $ 67.20 | ||||
Total shares issued as of December 31, 2023 (in shares) | 156,250 | 171,232 | 136,363 |
Employee Benefit Plan - Additio
Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2021 | |
Retirement Benefits [Abstract] | ||
Percentage of employer contribution | 50% | |
Maximum annual contribution per employee | 6% | |
Contributions made by employer | $ 0.1 | $ 0.1 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Detail) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Taxes [Line Items] | |||
Income tax provision | $ 0 | $ 200,000 | $ 115,000 |
Increase in valuation allowance | 4,600,000 | ||
Tax credit carryforward | 2,215,000 | $ 1,931,000 | |
Uncertain tax positions | 0 | ||
Increase decrease in uncertain tax position reasonably possible | 0 | ||
Domestic Tax Authority | |||
Income Taxes [Line Items] | |||
Net operating loss carryforwards | 109,500,000 | ||
Domestic Tax Authority | Research And Development | |||
Income Taxes [Line Items] | |||
Tax credit carryforward | 2,200,000 | ||
Domestic Tax Authority | Capital Loss Carryforward | |||
Income Taxes [Line Items] | |||
Tax credit carryforward | 1,800,000 | ||
Expire in 2035 to 2037 | Domestic Tax Authority | |||
Income Taxes [Line Items] | |||
Net operating loss carryforwards | $ 38,800,000 | ||
Maximum percentage of taxable income limited to offset by net operating loss carryforwads. | 100% | ||
Indefinite | Domestic Tax Authority | |||
Income Taxes [Line Items] | |||
Net operating loss carryforwards | $ 70,700,000 | ||
Maximum percentage of taxable income limited to offset by net operating loss carryforwads. | 80% | ||
M&F TTP Holdings LLC | |||
Income Taxes [Line Items] | |||
Amount of cash savings percentage | 85% |
Income Taxes - Schedule of Effe
Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |||
U.S. statutory tax benefit | $ (5,453) | $ (5,223) | $ (3,699) |
Partnership income (federal) not subject to tax to the Company | 1,200 | 1,241 | 996 |
Foreign withholding tax | 0 | 158 | 91 |
State taxes (net of federal benefit) | (2) | 28 | (14) |
Research and development tax credit | (273) | (172) | (173) |
Other | (64) | 40 | 10 |
Change in valuation allowance | 4,592 | 4,128 | 2,904 |
Provision for income taxes | $ 0 | $ 200 | $ 115 |
Effective income tax rate | 0% | (0.80%) | (0.70%) |
Income Taxes - Schedule of Net
Income Taxes - Schedule of Net Deferred Tax Assets/(Liabilities) (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred tax assets: | ||
Net operating loss carryforwards | $ 23,718 | $ 20,314 |
R&D Tax Credit carryforwards | 2,215 | 1,931 |
Investment in partnerships | 2,726 | 2,202 |
Charitable contributions | 3 | 3 |
Capital loss carryforward | 380 | 0 |
Total deferred tax assets | 29,042 | 24,450 |
Valuation allowance | (29,042) | (24,450) |
Net deferred tax assets | $ 0 | $ 0 |
Restructuring - Additional Info
Restructuring - Additional Information (Detail) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Restructuring Cost And Reserve [Line Items] | ||
Cash payments | $ 1.5 | $ 0.1 |
Restructuring workforce employee affected percentage | 65% | |
Restructuring costs | $ 1.6 | |
Research and development | ||
Restructuring Cost And Reserve [Line Items] | ||
Restructuring costs | 0.7 | |
General and administrative | ||
Restructuring Cost And Reserve [Line Items] | ||
Restructuring costs | 0.9 | |
Retirement and Consulting Agreement | ||
Restructuring Cost And Reserve [Line Items] | ||
Cash payments | $ 0.6 | 0.1 |
Additional severance costs | 0.5 | |
Additional consulting fees | $ 0.2 |
Net Loss per Share - Reconcilia
Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Numerator: | |||
Net loss | $ (25,966) | $ (25,073) | $ (17,731) |
Less: Net loss attributable to noncontrolling interests | (5,716) | (5,909) | (4,744) |
Net loss attributable to vTv Therapeutics Inc. | (20,250) | (19,164) | (12,987) |
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic | (20,250) | (19,164) | (12,987) |
Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted | $ (20,250) | $ (19,164) | $ (12,987) |
Class A Common Stock | |||
Denominator: | |||
Weighted average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) | 2,084,973 | 1,919,788 | 1,566,204 |
Weighted average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) | 2,084,973 | 1,919,788 | 1,566,204 |
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (usd per share) | $ (9.71) | $ (9.98) | $ (8.29) |
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (usd per share) | $ (9.71) | $ (9.98) | $ (8.29) |
Net Loss per Share - Schedule o
Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Dilutive Net Loss per Share (Detail) - shares | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) | 903,141 | 866,294 | 804,083 |
Class B Common Stock | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) | 577,349 | 577,349 | 577,349 |
Common stock options granted under the Plan | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) | 249,247 | 208,586 | 176,375 |
Common stock warrants | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) | 76,545 | 80,359 | 50,359 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |||
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] | Other income – related party | ||
Significant Unobservable Inputs (Level 3) | |||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |||
Beginning balance | $ 684 | $ 1,262 | $ 2,871 |
Net Change in fair value included in earnings | (574) | (946) | (1,609) |
Purchases / Issuance | 0 | 368 | 0 |
Sales / Repurchases | 0 | 0 | 0 |
Ending balance | 110 | 684 | $ 1,262 |
Fair Value, Measurements, Recurring | |||
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] | |||
Liabilities: | 110 | 684 | |
Fair Value, Measurements, Recurring | Warrant Liability, Related Party | |||
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] | |||
Liabilities: | 684 | ||
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | |||
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] | |||
Liabilities: | 0 | 0 | |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant Liability, Related Party | |||
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] | |||
Liabilities: | 0 | ||
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | |||
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] | |||
Liabilities: | 0 | 0 | |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Warrant Liability, Related Party | |||
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] | |||
Liabilities: | 0 | ||
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | |||
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] | |||
Liabilities: | $ 110 | 684 | |
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Warrant Liability, Related Party | |||
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] | |||
Liabilities: | $ 684 |
Fair Value of Financial Instr_4
Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |||
Fair value equity transfers in and out of level 3 instruments | $ 0 | $ 0 | $ 0 |
Fair Value of Financial Instr_5
Fair Value of Financial Instruments - Assumption Used to Calculate Fair Value of Warrants (Detail) | Dec. 31, 2023 | Dec. 31, 2022 |
CinRx Warrants | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Expected life of options in years | 3 years 6 months | |
Expected volatility | CinRx Warrants | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Inputs utilized in the valuation of warrants | 0.821 | |
Risk-free interest rate | CinRx Warrants | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Inputs utilized in the valuation of warrants | 0.040 | |
Expected dividend yield | CinRx Warrants | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Inputs utilized in the valuation of warrants | 0 | |
Minimum | Expected volatility | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Inputs utilized in the valuation of warrants | 0.7996 | 0.7694 |
Minimum | Risk-free interest rate | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Inputs utilized in the valuation of warrants | 0.0401 | 0.0411 |
Maximum | Expected volatility | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Inputs utilized in the valuation of warrants | 0.8961 | 0.8588 |
Maximum | Risk-free interest rate | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Inputs utilized in the valuation of warrants | 0.0487 | 0.0443 |
Weighted Average | Expected volatility | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Inputs utilized in the valuation of warrants | 0.8155 | 0.8217 |
Weighted Average | Risk-free interest rate | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Inputs utilized in the valuation of warrants | 0.0415 | 0.0419 |
Subsequent Events - Additional
Subsequent Events - Additional Information (Detail) - Subsequent Event - USD ($) $ / shares in Units, $ in Millions | Feb. 27, 2024 | Mar. 05, 2024 | Feb. 28, 2024 | Feb. 28, 2024 | Feb. 28, 2024 |
Subsequent Event [Line Items] | |||||
Entity public float, threshold | $ 75 | ||||
Percent of public float | 33.30% | 300% | |||
Private Placement | |||||
Subsequent Event [Line Items] | |||||
Proceeds from issuance of private placement | $ 51 | ||||
Private placement, shares (in shares) | 116,493 | ||||
Private placement pre-funded warrants, shares (in shares) | 116,590 | ||||
Private Placement | Private Placement Pre-Funded Warrants | |||||
Subsequent Event [Line Items] | |||||
Exercise price of warrants (usd per share) | $ 0.01 | ||||
TD Cowen Sales Agreement | |||||
Subsequent Event [Line Items] | |||||
Entity public float, threshold | 75 | ||||
Class A Common Stock | Private Placement | |||||
Subsequent Event [Line Items] | |||||
Shares sold (in shares) | 464,377 | ||||
Share price (usd per share) | $ 11.81 | ||||
Class A Common Stock | Private Placement | Private Placement Pre-Funded Warrants | |||||
Subsequent Event [Line Items] | |||||
Share price (usd per share) | $ 11.80 | ||||
Warrants to purchase shares of common stock (in shares) | 3,853,997 | ||||
Class A Common Stock | TD Cowen Sales Agreement | |||||
Subsequent Event [Line Items] | |||||
Aggregate offering price | $ 50 |